

Cite this: *Nanoscale Adv.*, 2024, 6, 1145

# Antimicrobial peptide-conjugated phage-mimicking nanoparticles exhibit potent bactericidal action against *Streptococcus pyogenes* in murine wound infection models†

Johanna Olesk,<sup>a</sup> Deborah Donahue,<sup>b</sup> Jessica Ross,<sup>c</sup> Conor Sheehan,<sup>d</sup> Zach Bennett,<sup>a</sup> Kevin Armknecht,<sup>e</sup> Carlie Kudary,<sup>f</sup> Juliane Hopf,<sup>f</sup> Victoria A. Ploplis,<sup>b</sup> Francis J. Castellino,<sup>b</sup> Shaun W. Lee<sup>c</sup> and Prakash D. Nallathamby<sup>b,\*†</sup>

*Streptococcus pyogenes* is a causative agent for strep throat, impetigo, and more invasive diseases. The main reason for the treatment failure of streptococcal infections is increased antibiotic resistance. In recent years, infectious diseases caused by pyogenic streptococci resistant to multiple antibiotics have been rising with a significant impact on public health and the veterinary industry. The development of antibiotic resistance and the resulting emergence of multidrug-resistant bacteria have become primary threats to the public health system, commonly leading to nosocomial infections. Many researchers have turned their focus to developing alternative classes of antibacterial agent based on various nanomaterials. We have developed an antibiotic-free nanoparticle system inspired by naturally occurring bacteriophages to fight antibiotic-resistant bacteria. Our phage-mimicking nanoparticles (PhaNPs) display structural mimicry of protein-turret distribution on the head structure of bacteriophages. By mimicking phages, we can take advantage of their evolutionary constant shape and high antibacterial activity while avoiding the immune reactions of the human body experienced by biologically derived phages. We describe the synthesis of hierarchically arranged core-shell nanoparticles, with a silica core conjugated with silver-coated gold nanospheres to which we have chemisorbed the synthetic antimicrobial peptide Syn-71 on the PhaNPs surface, and increased the rapidity of the antibacterial activity of the nanoparticles (PhaNP@Syn71). The antibacterial effect of the PhaNP@Syn71 was tested *in vitro* and *in vivo* in mouse wound infection models. *In vitro*, results showed a dose-dependent complete inhibition of bacterial growth (>99.99%). Cytocompatibility testing on HaCaT human skin keratinocytes showed minimal cytotoxicity of PhaNP@Syn71, being comparable to the vehicle cytotoxicity levels even at higher concentrations, thus proving that our design is biocompatible with human cells. There was a minimum cutoff dosage above which there was no evolution of resistance after prolonged exposure to sub-MIC dosages of PhaNP@Syn71. Application of PhaNP@Syn71 to a mouse wound infection model exhibited high biocompatibility *in vivo* while showing immediate stabilization of the wound size, and infection free wound healing. Our results suggest the robust utility of antimicrobial peptide-conjugated phage-mimicking nanoparticles as a highly effective antibacterial system that can combat bacterial infections consistently while avoiding the emergence of resistant bacterial strains.

Received 8th August 2023  
Accepted 8th January 2024

DOI: 10.1039/d3na00620d

rsc.li/nanoscale-advances

## 1 Introduction

*Streptococcus pyogenes*, otherwise known as a  $\beta$ -hemolytic Gram+ Group A Streptococcus (GAS), is currently one of the

significant problems in the global healthcare system, especially in hospital-acquired infections.<sup>1–3</sup> It causes a wide range of infections, varying from mild pathologies such as pharyngotonsillitis to severe invasive infections such as necrotizing

<sup>a</sup>Department of Aerospace and Mechanical Engineering, University of Notre Dame, Notre Dame, Indiana, USA. E-mail: pnallath@nd.edu; Tel: +1 574 631 7868

<sup>b</sup>W. M. Keck Center for Transgene Research, University of Notre Dame, Notre Dame, Indiana, USA

<sup>c</sup>Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, USA

<sup>d</sup>Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA

<sup>e</sup>Department of Pre-Professional Studies, University of Notre Dame, Notre Dame, Indiana, USA

<sup>f</sup>Berthiaume Institute for Precision Health, University of Notre Dame, Notre Dame, Indiana, USA

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3na00620d>



fasciitis and sepsis,<sup>4–6</sup> with one-fifth of the invasive infections being severe bloodstream infections.<sup>7</sup> *S. pyogenes* mainly infects school-aged children and young adults. However, they have the potential to infect people of all ages. In the United States alone, 11 000–24 000 people suffer from a severe GAS disease, with almost 2000 dying directly due to *S. pyogenes* infections,<sup>4</sup> making it a top 10 cause of death globally. The prevalence of *S. pyogenes* infections in the USA has almost doubled, increasing from 3.4 to 4.3 per 100 000 people in 2012 to 7.26 per 100 000 people in 2017,<sup>8</sup> mainly due to changes in virulence,<sup>9</sup> or the development of antibiotic resistance in *S. pyogenes* or through co-infection with other antibiotic-resistant bacteria such as *Staphylococcus aureus*.<sup>10,11</sup>

Antibiotics have been the primary method of treating bacterial infections, including *S. pyogenes* infections. For decades, the gold standard of treatment of *S. pyogenes* infections has been penicillin.<sup>12</sup> Due to irresponsible, widespread use of antibiotics,<sup>10</sup> and the last new class of antibiotics being introduced in 2003,<sup>13</sup> bacteria have developed antibiotic resistance from chronic exposure to low levels of antibiotics over long periods, allowing the bacteria to adapt and build survival mechanisms against antibiotics. Antibiotic resistance is an increasingly growing global health concern. Like other bacteria, *S. pyogenes* can also develop antibiotic resistance, making the infections more challenging to treat as the treatment becomes ineffective.<sup>14–16</sup> Although *S. pyogenes* has remained relatively susceptible to  $\beta$ -lactam antibiotics, the resistance has increased radically in recent years.<sup>15</sup> It has been reported that in approximately 35% of pharyngotonsillitis patients, the eradication of *S. pyogenes* fails due to bacterial antibiotic resistance.<sup>16</sup> Therefore, several studies have focused their research on developing alternative methods against antibiotic-resistant bacteria.<sup>17</sup> There are various approaches that could provide the potential to treat antibiotic-resistant bacterial infections, such as antimicrobial peptides, phage therapy, or nanoparticle-based systems.

The development of antibacterial nanoparticles has become one of the most researched areas to fight antibiotic-resistant infections.<sup>18–22</sup> An advantage of nanoparticles is that they can be designed to be target-specific, reducing toxicity to human cells and tissues. Metal nanoparticles have been extensively studied and are among the most promising antibacterial nanoparticles, showing strong antibacterial effect *via* various mechanisms of action,<sup>23</sup> including the generation of reactive oxygen species (ROS), the release of cations, bacterial membrane binding, and disruption due to their positive charge, and biomolecular damage by interacting with biomolecules, such as lipopolysaccharides.<sup>24,25</sup> Heavy metal nanoparticles, such as silver nanoparticles, generate ROS with high affinity to thiol (–SH) carriers such as cysteine.<sup>25,26</sup> This affinity breaks the disulfide (–S–S–) bridges of the proteins and disrupts enzymatic functions, leading to cell death. The antibacterial properties of silver have been a widely researched area due to its long history of usage in treating infections,<sup>27</sup> with silver nanoparticles being the most effective against bacteria.<sup>28</sup> Silver nanoparticles have unique physicochemical properties, such as size distribution, agglomeration, surface chemistry, and ion release, that influence their biological activity.<sup>29</sup> Silver nanoparticle have the

ability to adhere to bacterial cell walls and membranes, penetrate the cells and bind with bacterial biomolecules, causing their disruption and intracellular damage.<sup>29–31</sup> More importantly, silver nanoparticles generate ROS and free radicals that trigger the oxidative stress of the bacterial cell and interfere with bacterial signal transduction pathways.<sup>30</sup> However, silver-generated ROS have been shown to exhibit significant toxic effects on human cells despite their counterbalancing by the activation of the eukaryotic antioxidant network, which severely limits silver nanoparticle use for treating infections.<sup>32,33</sup>

More recent studies have focused on the synergistic antibacterial effect exhibited by the nanoparticles and antimicrobial peptides (AMPs) to enhance the overall antibacterial effect.<sup>17,34–36</sup> All these studies focused on electrostatic immobilization of the AMPs on silver nanoparticles, unlike ours, which has the AMP chemisorbed on gold-silver nano turrets on a silica core. AMPs are an important novel source of antibacterial compounds as an alternative to conventional antibiotics. They are usually positively charged short peptides, existing as part of the innate immune system of humans, animals, and plants. AMPs exhibit a broad antibacterial spectrum with complex mechanisms induced by the direct interactions of the peptides with bacterial membranes, leading to membrane disruption or entry into the bacterial cell and interactions with intracellular components.<sup>8,37</sup> Acting through various mechanisms reduces the possibility of bacteria developing resistance towards AMPs compared to antibiotics.<sup>38</sup> To make AMPs more biocompatible and increase their effectiveness and stability, researchers have created synthetic AMPs and developed combinations of nanoparticles and AMPs to induce synergistic effects.<sup>39</sup>

Here, we discuss the significant antibacterial activity and high biocompatibility of modularly assembled phage-mimicking nanoparticles (PhaNPs) capped with a rationally designed, cysteine-modified, antimicrobial peptide (Syn-71) (Fig. 1). Our nanoparticle design was based on the structure of tailless bacteriophages, taking advantage of assembling antibacterial components hierarchically in order to maximize the desired antibacterial effects while minimizing the toxicity of the particles to human cells. PhaNPs are composed of a silica core with silver-coated gold nanospheres distributed on the silica surface to mimic the protein turret on the surface of bacteriophages.<sup>40</sup> The combination of hierarchically arranged materials allows the PhaNPs to inhibit bacterial growth and kill pathogenic bacteria. It was shown that this hierarchical design is highly bacteriostatic (99.9% retardation in *Staphylococcus aureus* USA300, *Pseudomonas aeruginosa* FRD1, *Enterococcus faecalis*, and *Corynebacterium striatum*) while showing little toxicity to mammalian cells. We have made the PhaNPs rapidly bactericidal by chemisorbing synthetic antimicrobial Syn71 peptide on to the gold-silver nanodots on the PhaNPs. Syn71 peptide is highly bactericidal to the human pathogen *S. pyogenes*, but its therapeutic window is limited by its toxicity to human cells at doses higher than 8  $\mu$ M.<sup>40,41</sup> By incorporating the peptide onto the overall PhaNPs design, we hypothesized that we would be able to increase the rapidity of bactericidal activity of our nanoparticles towards *S. pyogenes* while keeping the cytotoxicity of the nanoparticles towards mammalian cells





**Fig. 1** The overall experimental workflow. (A) A visual representation of the modular assembly of PhaNP@Syn71 synthesis workflow, (B) *in vitro* bacteria growth inhibition testing workflow, (C) *in vivo* mouse wound infection model experimental workflow, (D) antibacterial mechanisms of PhaNP@Syn71 is through the synergistic effect of PhaNPs and Syn71. Bacterial membrane penetration by Syn71 peptides on PhaNP@Syn71 enhances the period of contact of PhaNPs with the bacteria, disrupting the bacterial integrity. Illustrations are not to scale.

minimal. The antibacterial effect of the PhaNP@Syn71 was tested *in vitro* and *in vivo* against *S. pyogenes*. *In vitro* results displayed dose-dependent bactericidal activity (up to >99.99%). Cytocompatibility testing of PhaNP@Syn71 on HaCaT human skin keratinocytes showed significantly low cytotoxicity, the toxicity levels being comparable to the vehicle level even at the highest concentration tested (up to 64  $\mu\text{M}$ ), demonstrating the biocompatibility of our designed nanoparticle system with human cells. *In vitro* evolution of resistance studies indicated a cutoff sub-MIC dosage above which there was no evolved resistance of *S. pyogenes* to PhaNP@Syn71 after repeated exposure of  $\sim 1000$  generations of *S. pyogenes* to PhaNP@Syn71. *In vivo* studies on a mouse wound infection model exhibited immediate wound size stabilization compared to wound flaring in controls while showing no toxicity to the surrounding mammalian cells and mouse organs. Our results suggest that PhaNP@Syn71 has opened the door for a new class of antibacterial nanocarriers that can sterically separate and orient antimicrobial peptides to be a highly effective antibacterial system to combat bacterial infections without antibiotics and prevent the emergence of antibiotic resistance.

## 2 Materials and methods

### 2.1 Materials

*Streptococcus pyogenes* strain AP53 Covs+; LB broth (Miller; Sigma-Aldrich); agar (Sigma-Aldrich); 200 proof ethanol (VWR); 20% v/v ammonium hydroxide ( $\text{NH}_4\text{OH}$ ; BDH); tetraethyl orthosilicate (TEOS; Sigma Aldrich, 99% GC grade); 3-aminopropyltriethoxysilane (APTES; Sigma Aldrich, 99%); sodium hydroxide ( $\text{NaOH}$ ; Sigma Aldrich, >97%); sodium citrate dihydrate ( $\text{C}_6\text{H}_5\text{Na}_3\text{O}_7 \cdot 2\text{H}_2\text{O}$ ; Sigma Aldrich, >99%); tetrakis(hydroxymethyl)phosphonium chloride (80% purity) (THPC; Sigma Aldrich, 80% in water); gold chloride (anhydrous; Sigma Aldrich); silver nitrate ( $\text{AgNO}_3$ ; Sigma Aldrich, 99% ACS grade); hydroquinone (Sigma Aldrich, >99% reagent grade); deionized water (DI water); 4% buffered paraformaldehyde (VWR), phosphate-buffered saline (PBS) without calcium and magnesium (1X; Cytiva); rhodamine B isothiocyanate (Sigma-Aldrich); AFdye488-Maleimide (Fluoroprobes), Cys-Syn71 peptide (CAG-TEKIFQRLKKTIQEGKKIAKRWW, GenScript).

### 2.2 Nanoparticle synthesis

**2.2.1 Silica core synthesis.** To synthesize silica ( $\text{SiO}_2$ ) core nanoparticles, the sol-gel (Stöber) method of hydrolysis and condensation of TEOS was used, yielding monodispersed silica nanoparticles with a diameter of 25 nm. In a 100 ml glass beaker with a magnetic stir bar, 30 ml of ethanol, 6 ml of DI water, and 1.8 ml of 20% v/v  $\text{NH}_4\text{OH}$  were added. The mixture was stirred with an even vortex and 1.125 ml of TEOS was added to the mixture. The mixture was left to stir at room temperature (22  $^\circ\text{C}$ ) overnight (minimum of 12 h). The  $\text{SiO}_2$  cores were centrifuged at 9000 RCF for 30 min at room temperature to settle the  $\text{SiO}_2$  nanoparticles in the pellet and separate the supernatant. The nanoparticle-containing pellet was washed with 10 ml ethanol, sonicated (pulse for 20 s at 40% amplitude), and rinsed with 30 ml ethanol by centrifugation twice.

**2.2.2 Red fluorescent silica core synthesis.** Red-fluorescent silica cores were synthesized using the same procedure as Section 2.2.1 with one modification. Rhodamine B isothiocyanate-aminopropyltriethoxy silane (0.125 mL) was mixed with 1 ml of TEOS and utilized instead of 1.125 ml of TEOS.

**2.2.3 Silica core silanization.** The silica cores were amine-functionalized by adding 25 ml ethanol, 5 ml DI water, and 1 ml APTES with the silica cores pellets into a 100 ml beaker. The solution was stirred overnight with a smooth vortex at room temperature, yielding  $\text{SiO}_2$ -APTES cores. The solution was centrifuged at 9000 rpm for 30 min at room temperature to separate the supernatant. The  $\text{SiO}_2$ -APTES nanoparticle pellets were washed with 10 ml ethanol, sonicated (pulse for 20 s at 40% amplitude), and rinsed with 30 ml ethanol by centrifugation. After discarding the supernatant, the pellet was resuspended in 10 ml of DI water, sonicated (pulse for 20 s at 40% amplitude), and transferred into a 100 ml beaker with additional 20 ml DI water.

**2.2.4 Gold nanosphere synthesis.** Gold nanospheres with a diameter of 5 nm were synthesized using a modified procedure of alkaline reduction.<sup>42</sup> Into a 250 ml beaker 43.16 ml DI



**Table 1** Syn-larvacin peptide antibacterial effect against *S. pyogenes*. Minimum Inhibitory Concentration (MIC) and Minimal Bactericidal Concentration (MBC) are shown for each Syn-larvacin variant

Peptide variant	Sequence (N-C)	MIC ( $\mu\text{M}$ )	MBC ( $\mu\text{M}$ )
Scaffold sequence	AGKETIRQFLKKKIQEKGKRATIAW	8	64
Syn-larvacin-27	AGKETIFRLKKKIQEKGKRAWIAW	0.125	0.5
Syn-larvacin-31	AGTEKIFRLKKWIQEGKKIAKRAW	0.25	0.25
Syn-larvacin-40	AWTEKIFNRLKKTINEGKKIAKRAW	0.25	4
Syn-larvacin-67	AGKETIFRLKKKIQEKGKRATIIWW	0.25	0.25
Syn-larvacin-69	AGKETIRQFLKKTIQEKGKRATIIWW	0.125	0.5
Syn-larvacin-71	AGTEKIFRLKKTIQEGKKIAKRW	0.125	0.125
PhaNp@Syn-71	CAGTEKIFRLKKTIQEGKKIAKRW	8.62	50
Syn-larvacin-72	AGTEKIFNRLKKTINEGKKIAKRW	0.125	2

water, 427  $\mu\text{l}$  NaOH (1 M), 3.21 ml sodium citrate (68 mM), and 1.07 ml THPC (85 mM) were added. The solution was stirred with a smooth vortex for at least 10 min at room temperature, and then 2.14 ml of gold chloride (25 mM) was added. The solution was stirred agitation free at room temperature overnight in the dark.

**2.2.5 Gold nanosphere deposition to silica cores.** The gold nanosphere solution was mixed with  $\text{SiO}_2$ -APTES nanoparticle solution in a ratio of 1 : 2 and stirred overnight in the dark with a smooth vortex, yielding  $\text{SiO}_2$ @Au core-shell nanoparticles. The solution was centrifuged at 9000 RCF for 15 min at room temperature. The pellet was washed with 10 ml ethanol, sonicated (pulse for 20 s at 40% amplitude), and rinsed with 30 ml ethanol by centrifugation.

**2.2.6 Silver coating of gold nanospheres.** Silver is alloyed onto gold nanospheres previously conjugated onto  $\text{SiO}_2$  nanoparticles using the reduction reaction by hydroquinone.<sup>43</sup>  $\text{SiO}_2$ @Au nanoparticle solution (30 mL) was mixed with 7.2 ml 10 mM  $\text{AgNO}_3$  and 5.76 ml 10 mM freshly prepared hydroquinone. The mixture was stirred at 500 rpm overnight in the dark, followed by halting the silver coating reaction by centrifugation and discarding the supernatant.  $\text{SiO}_2$ @Au@Ag (PhaNPs) pellet was washed with 30 ml DI water two times, sonicated (pulse for 20 s at 40% amplitude) and rinsed by centrifugation at 9000 RCF for 15 min at room temperature.

**2.2.7 Antimicrobial peptide immobilization onto PhaNP.** A 1.27 mM Syn71 peptide stock in 1X PBS was prepared. Syn71 peptide developed from a library of peptides by Ross *et al.*<sup>41</sup> was used due to its high antibacterial activity. Syn71 in this study refers to syn-larvacin 71 peptide (Table 1) terminated with an additional cysteine (Cys) residue on the N-terminal. Syn71 peptide was cysteine terminated to increase the probability of them being chemisorbed to the gold or silver surface *via* the sulfur atom.<sup>44–46</sup> The immobilization of peptides on the gold or silver surface is also possible through amines or amides.<sup>47</sup> The PhaNP pellet was resuspended in 1X PBS to create a buffered environment for the Syn71 peptide. In a 100 ml beaker, 30 ml of resuspended PhaNP were mixed with 1 ml of 1.27 mM Syn71 peptide solution. The mixture was stirred in the dark at room temperature at 500 rpm for at least 36 hours to allow maximum chemisorption of the peptide onto the nanoparticles, yielding

PhaNp@Syn71 nanoparticles. The PhaNP@Syn71 solution was centrifuged for 15 min at 9000 rpm at room temperature to separate the supernatant. The pellet was washed with 15 ml of 1X PBS, sonicated (pulse for 10 s at 30% amplitude), and rinsed by centrifugation. Both supernatants were saved and stored in the freezer ( $-20\text{ }^\circ\text{C}$ ) to quantify the peptide absorbed onto the nanoparticles using Liquid Chromatography Mass Spectroscopy (LC-MS).

### 2.3 Nanoparticle characterization

**2.3.1 TEM imaging.**  $\text{SiO}_2$  core and PhaNP@Syn71 nanoparticle samples were prepared for TEM analysis by drop coating the dispersed sample onto a 300-mesh copper grid coated with amorphous carbon film. TEM images of the  $\text{SiO}_2$  core and PhaNP@Syn71 nanoparticles were obtained on a JEOL 2011 microscope at an acceleration voltage of 200 kV. Further image analysis was carried out using ImageJ software. The diameters of  $\text{SiO}_2$  core nanoparticles ( $n = 188$ ) and PhaNP@Syn71 nanoparticles ( $n = 214$ ) were measured from several selected TEM images, and the average diameters of both samples were calculated.

**2.3.2 Scanning electron microscope (SEM) with energy-dispersive X-ray spectrum (EDXS) analysis.** To analyze the nanoparticle elemental content and confirm the presence of silica, gold, and silver, SEM in conjunction with energy-dispersive X-ray spectrum (EDXS) analysis was carried out on Thermo Scientific Prisma E-SEM at an acceleration voltage of 15 kV, current of 70 pA and magnification of 100 000 $\times$ . A drop of resuspended PhaNP sample was placed onto an aluminum SEM stub and dried under a vacuum. An EDXS map was created to scan over a site of PhaNP on the stub, with a count rate of 993 cps.

**2.3.3 Inductively coupled plasma-optical emission spectroscopy (ICP-OES) for nanoparticle elemental quantification.** ICP-OES was performed on PerkinElmer Optima 8000 to quantify the elemental distribution of silica (Si), gold (Au), and silver (Ag). Si, Au, and Ag standards (0, 0.2, 2, 4, and 10 ppm) were prepared from commercially available 1000 ppm Si, Au, and Ag(II) standard solutions and dissolved in 5% Aqua Regia.  $\text{SiO}_2$ NP,  $\text{SiO}_2$ AuNP, and PhaNP (200  $\mu\text{l}$ ) samples were dissolved overnight in 500  $\mu\text{l}$  of 100% Aqua Regia (3 : 1 hydrochloric acid :



nitric acid), followed by the addition of 9.5 ml DI water to a final concentration of 5% Aqua Regia. Si, Au, and Ag emission spectra were collected at 251.611 nm, 267.595 nm, and 328.068 nm, respectively. Emission spectra for yttrium (Y), an internal standard, were collected at 371.029 nm.

**2.3.4 Liquid chromatography-mass spectrometry (LC-MS) analysis.** The supernatant collected after peptide modification of the PhaNPs was used for the quantification of the amount of Syn71 peptide absorbed onto the PhaNPs by back-calculation from the amount remaining in the supernatant. The supernatant samples were stored in the freezer ( $-20\text{ }^{\circ}\text{C}$ ) until analyzed by LC-MS. The LC-MS instrument consisted of a Dionex Ultimate 3000 Rapid Separation UPLC system equipped with a Dionex Ultimate 3000 autosampler and a Dionex Ultimate 3000 photodiode array detector coupled with a Bruker MicroTOF-Q II quadrupole time-of-flight hybrid mass spectrometer using Hystar 3.2 software. The Bruker electrospray ionization source was operated in the positive ion mode with the following parameters: end plate offset voltage =  $-500\text{ V}$ , capillary voltage =  $2000\text{ V}$ , and nitrogen as both a nebulizer ( $4\text{ bar}$ ) and dry gas ( $8\text{ L min}^{-1}$  flow rate at  $180\text{ }^{\circ}\text{C}$  temperature). Mass spectra were accumulated over the mass range  $400\text{--}3000\text{ Da}$ . The sample was analyzed on a Dionex Acclaim<sup>TM</sup> RSLC 120 C8 column ( $2.2\text{ }\mu\text{m}$ ,  $120\text{ \AA}$ ,  $2.1\text{ mm i.d.} \times 100\text{ mm}$ ). The mobile phase (A =  $0.1\%$  formic acid in water; B =  $0.1\%$  formic acid in acetonitrile) gradient consisted of elution at  $0.4\text{ ml min}^{-1}$  with  $90\%$  A/ $10\%$  B for  $1.5\text{ min}$ , followed by a  $6.9\text{ min}$  linear gradient to  $5\%$  A/ $95\%$  B, an  $0.1\text{ min}$  linear gradient to  $90\%$  A/ $10\%$  B, and then  $90\%$  A/ $10\%$  B for  $1.5\text{ min}$ . LC flow was diverted to the waste for the first  $1.4\text{ min}$ . Peak areas from extracted ion chromatograms (EICs) of corresponding  $m/z$  values were quantified.

### 2.3.5 Dynamic light scattering (DLS) and electrophoretic light scattering (ELS)

**2.3.5.1. Dynamic light scattering (DLS).** The size distributions of the plain and peptide-bearing nanoparticles were measured using a Malvern Zetasizer Nano-ZS (Model ZEN3600) instrument by performing DLS. Each DLS sample was prepared by diluting  $100\text{ }\mu\text{l}$  of the nanoparticle stock solution with  $900\text{ }\mu\text{l}$  of  $1\text{X}$  phosphate-buffered saline (PBS). The resulting dilutions were carefully pipetted into  $1\text{ ml}$  polystyrene cuvettes (Malvern part number DTS0012) to prevent bubble formation. The cuvettes were loaded into the Zetasizer one at a time by orienting the arrow onto the cuvette to the arrow on the instrument and closing the device's lid. The Malvern Zetasizer software was used to take the size measurements. The program uses the absorption and refractive index of the nanoparticle's silica core material ( $R_i = 1.459$ ,  $A = 0.035$ ) and the refractive index, dielectric constant, and viscosity of the PBS dispersant ( $(R_i)_{\text{PBS}} = 1.330$ ,  $K = 79$ ,  $\mu = 0.8882\text{ cP}$ ) as well as its internal measurements to determine the size distribution of the nanoparticles. The instrument reports three size distributions that correspond to the three trials the instrument automatically performs when run. The software determines the sizes reported for each trial by averaging eleven different measurements taken during each trial.

**2.3.5.2. Electrophoretic light scattering (ELS).** The zeta potential values of the plain and peptide-bearing nanoparticles were also found with the Malvern Zetasizer Nano-ZS (Model ZEN3600) instrument by performing ELS. Each ELS sample was prepared by diluting  $100\text{ }\mu\text{l}$  of the nanoparticle stock solution with  $900\text{ }\mu\text{l}$  of  $1\text{X}$  phosphate-buffered saline (PBS), as was done for the DLS samples. These dilutions were carefully pipetted into folded capillary zeta cells (Malvern part number DTS1070) to prevent bubble formation. These cells were loaded into the warmed Zetasizer one at a time by matching the arrow on the cell to the arrow on the instrument and closing the device's lid. The Malvern Zetasizer Nano-ZS software was used to take the zeta potential measurements. The program uses the absorption and refractive index of the silica core material ( $(R_i)_{\text{Si}} = 1.459$ ,  $A = 0.035$ ) and the refractive index, dielectric constant, and viscosity of the PBS dispersant ( $(R_i)_{\text{PBS}} = 1.330$ ,  $K = 79$ ,  $\mu = 0.8882\text{ cP}$ ) as well as its internal measurements to determine the zeta potential. The instrument reports three zeta potential measurements that correspond to the three trials the instrument automatically performs when run. The software displays the average zeta potential found over the  $100$  measurements the device takes during each trial.

## 2.4 Cytocompatibility testing

To test the cytocompatibility of the PhaNP@Syn71, HaCaT human epithelial keratinocytes were used. The cells were cultured and maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with  $10\%$  heat-inactivated fetal bovine serum (FBS) at  $37\text{ }^{\circ}\text{C}$  with  $5\%$   $\text{CO}_2$  in  $100\text{ mm}$  culture dishes. First, HaCaT cells were grown to  $75\text{--}80\%$  confluency in  $24\text{-well}$  tissue culture plates supplemented with DMEM. Before adding the samples (PhaNP@Syn71, PhaNPs, Syn71), DMEM was aspirated from the wells, and the cells were washed with  $1\text{X}$  PBS. The PBS was aspirated, and the sample solutions in DMEM were added to the wells with washed HaCaT cells. The cells were incubated at  $37\text{ }^{\circ}\text{C}$  with  $5\%$   $\text{CO}_2$  for  $16\text{ h}$ , after which DMEM was aspirated, and cells were washed with  $1\text{X}$  PBS to remove free nanoparticles. To determine the cytotoxicity of various concentrations of PhaNP@Syn71 as well as PhaNPs and Syn71 peptide alone, ethidium homodimer cell death assay<sup>30</sup> was used.  $4\text{ }\mu\text{M}$  ethidium homodimer in  $1\text{X}$  PBS was added to HaCaT cells and incubated at  $37\text{ }^{\circ}\text{C}$  for  $30\text{ min}$ . The plate reader was set to  $528\text{ nm}$  excitation and  $617\text{ nm}$  emission with a cutoff value of  $590\text{ nm}$  to determine the level of fluorescence. To determine the percentage of dead cells, all cells were permeabilized by the addition of  $0.1\%$  (w/v) saponin to each well after the initial reading, and incubated at room temperature for  $20\text{ min}$ , followed by shaking the plate on an orbital shaker. The plate reader was used in the same settings as before to measure the fluorescence. Percent membrane permeabilization was calculated by dividing the fluorescence values with intact cells by the fluorescence values after cell disruption by saponification. Each treatment condition was performed in triplicate, with the average cell viability (as a percent of the control) plus the standard deviation of all conditions plotted together for comparison.



**2.4.1 *In vitro* scratch closure assay.** *In vitro* scratch closure assay was carried out on HaCaT human epithelial keratinocytes by using a modified protocol by Liang *et al.*<sup>48</sup> The cells were cultured and maintained in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) at 37 °C with 5% CO<sub>2</sub> in 100 mm culture dishes until confluency reached 80–90%. HaCaT cells were prepared by washing the cells with 1X PBS. Trypsin was added, and cells were incubated at 37 °C for 5 minutes, followed by stopping trypsinization by adding DMEM. Cells were centrifuged at 1200 rpm for 12 min, and the pellet was resuspended in DMEM. An 8-well chamber slide was used, and 50 000 HaCaT cells were added to each well. Corresponding volumes of free Syn71 peptide (8 μM), SiO<sub>2</sub>AuNPs, and PhaNPs, volumes corresponding to the volume of PhaNP@Syn71 containing 4 μM or 8 μM Syn71 were added. Enough DMEM media was added to reach the final volume of 300 μl per well. The cells were allowed to attach to the well bottom for 26 h at 37 °C, followed by creating the scratch by using a sterile pipette tip to scrape the cell monolayer in a straight line. The chamber slide was live imaged under the microscope at 37 °C for 24 h.

## 2.5 Biocidal activity against planktonic bacteria

The antibacterial effect of various concentrations of PhaNP@Syn71 together with SiO<sub>2</sub>@Au nanoparticles, non-peptide PhaNPs and Syn71 peptide alone was screened against *S. pyogenes*. Growth curve measurements and CFU per ml assays were used to evaluate the overall antibacterial effect and are described below.

**2.5.1 Bacteria culture.** *S. pyogenes* blood agar plate was obtained from W. M. Keck Center for Transgene Research and kept in a fridge at +4 °C for up to two weeks. A single colony of *S. pyogenes* was picked from the agar plate and adapted to planktonic lifestyle in 6 ml LB media for 12 h at 37 °C under continuous shaking (300 rpm). This inoculum was used as a pre-culture for the plate reader-run, with the initial bacteria cell count after inoculation  $2.92 \times 10^7$  (OD<sub>600 nm</sub> = 0.48).

**2.5.2 Growth curve measurements.** At least four replicates of each sample and control were run on PerkinElmer Victor 31420 Multilabel Counter Plate Reader. As a background and positive control, pure LB media and the bacteria growing in LB media only were used. The tests were premixed in a 2 ml microcentrifuge tube, containing a total of 2 ml of solution, including 30 μl of bacteria inoculum and precalculated volumes of nanoparticle samples as well as Syn71 peptide alone. In addition, background solutions for each nanoparticle sample and concentration without bacteria were prepared. The solutions were mixed thoroughly, and 200 μl of the solution was pipetted into each well of a sterile 96-well plate and incubated under continuous shaking at 37 °C for 24 h with OD<sub>600 nm</sub> measurements taken every 10 min. The resulting growth curves were corrected with the LB media background as well as the nanoparticle backgrounds.

**2.5.3 Minimum inhibitory concentration.** The MIC of the PhaNP@Syn71 was determined by the method involving microdilution in culture broth, as indicated by the Clinical and

Laboratory Standards Institute of the United States of America.<sup>49</sup> In this process, 8 different concentrations of PhaNP@Syn71 w.r.t Syn71 on the PhaNPs, were used. The starting concentration w.r.t to PhaNP@Syn71 was 174 μM and it was serially diluted 6 more times by a factor of two to get seven concentrations of PhaNP@Syn71. The final sample had no PhaNP@Syn71 added and was designated as 0 μM of PhaNP@Syn71. Before the start of each experiment, solutions of PhaNP@Syn71 were prepared under aseptic conditions in sterile LB broth. The OD<sub>600 nm</sub> of the *S. pyogenes* inoculate was adjusted in LB media to be 0.01 absorbance before addition to the different concentrations of PhaNP@Syn71. Three to five replicates were performed for each concentration of PhaNP@Syn71. The minimum concentration at which 50% growth of bacteria was inhibited (MIC50) and at which 90% growth of bacteria was inhibited (MIC90) was measured from the growth curves. MIC can be defined as the lowest concentration of antibiotic that shows no OD<sub>600 nm</sub> above the background signal.<sup>50</sup>

**2.5.4 Evolution of resistance.** In this study, we exposed *S. pyogenes* strain to PhaNP@Syn71 using the method described by M. Lagator *et al.*<sup>51</sup> We evolved six replicate populations at three sub-MIC concentrations of PhaNP@Syn71 (0.1MIC, 0.2MIC and 0.35MIC), giving rise to 18 evolving populations, and a 'wild-type' population, propagated in the absence of PhaNP@Syn71. 0.1MIC is the 0.10X the maximal effective dose of PhaNP@Syn71. Similarly, 0.2MIC and 0.35MIC are 0.20X and 0.35x the maximal effective dose of a given PhaNP@Syn71. The MIC is the lowest antibiotic concentration that resulted in no measurable growth after 24 h. We obtained these concentrations by measuring a dose–response of the naïve population by transferring 1.5 μl of overnight culture to a serial dilution of each sub-MIC concentration, and measuring OD<sub>600 nm</sub> after 24 h of growth (EC50, MIC and 2MIC, respectively, for PhaNP@Syn71 – 4.79 μM; 8.62 μM; 17.24 μM). During the selection procedure, every 24 h 1.5 μl was transferred to 1.2 ml of fresh medium with the same PhaNP@Syn71 concentration. We immigrated half as much to the populations evolving at MIC10. After 28 days, we grew all populations in the absence of antibiotics for 24 h, so that all populations reached a similar density. Then, we transferred 1.5 μl of each culture into appropriate media, in order to measure the growth curves of the wild-type and of all evolved populations in (i) the absence of PhaNP@Syn71 and (ii) 0.5MIC, 0.9MIC and 2MIC of the PhaNP@Syn71 (three replicate measurements per population, with each set of replicates performed simultaneously), using a BioTek H1 plate reader. From these growth curves, we determined the maximum growth rate, as the greatest slope of the log-transformed growth curve. In addition, we measured the dose–response curves of all evolved populations in the manner described above to determine the emergence of resistance if any.

**2.5.5 CFU per ml assay.** The inoculum from a 96-well plate after growth curve measurements were collected for each sample from 3 wells of 200 μl (bacteria alone, bacteria with SiO<sub>2</sub>Au nanoparticles, PhaNPs, and all concentrations of PhaNP@Syn71). Serial dilutions were carried out by adding 100



$\mu\text{l}$  sample inoculum to 900  $\mu\text{l}$  LB media. Dilutions of  $10^{-3}$ ,  $10^{-4}$ ,  $10^{-5}$  and  $10^{-6}$  were plated for CFU per ml assay. Blood agar plates were used to plate at least 3 replicates of 10  $\mu\text{l}$  of each sample. The plates were incubated at 37 °C for 16–18 h. CFU per ml was calculated according to eqn (1).

$$\text{CFU per ml} = \frac{\text{counted CFU}}{\text{total inoculum volume}} \times \frac{1000 \mu\text{l}}{1 \text{ ml}} \times \frac{1}{\text{dilution factor}} \quad (1)$$

## 2.6 Bacteria imaging

### 2.6.1 Bacteria imaging with electron microscopy (EM).

Scanning Electron Microscopy (SEM) was carried out on Magellan 400 XHR. Bacteria samples were collected after the growth measurements, taking 400  $\mu\text{l}$  of each bacteria sample. Circular 12 mm coverslips were prepared by dipping them into 0.1% (w/v) poly-L-lysine for 15 min and air drying overnight. As a primary fixative, 2% glutaraldehyde was prepared in 0.1 M sodium cacodylate buffer (pH 7.5). As a secondary fixative, 1%  $\text{OsO}_4$  was used. The bacteria cells were centrifuged at 1200 rpm for 10 min, and the supernatant was removed. The samples were washed three times in 1X PBS by centrifugation. After the final centrifugation, the cells were resuspended in 100  $\mu\text{l}$  1X PBS, and 50  $\mu\text{l}$  of each sample was applied in duplicates onto separate poly-L-lysine coverslips prepared earlier and incubated for 15 min at room temperature. Glutaraldehyde fixative (500  $\mu\text{l}$ ) was added onto samples on coverslips and incubated for 1 h after which the coverslips were washed three times with sodium cacodylate buffer. The coverslips were further incubated with the  $\text{OsO}_4$  fixative for 1 h, rinsed three times with sodium cacodylate buffer, two times with DI water, and finally dehydrated with ethanol followed by replacing ethanol from the final dehydration step with liquid  $\text{CO}_2$  in a critical point dryer. Each coverslip was applied on the SEM stub and coated with iridium for imaging.

### 2.6.2 Bacteria imaging with maleimide AF488 dye and red fluorescent silica@Au NPs

#### 2.6.2.1 Maleimide AF488 staining for cysteine residues on fixed *S. pyogenes*.

*Streptococcus pyogenes* was grown in LB media for 16 hours. The bacteria were pelleted and fixed in 4% buffered para-formaldehyde for 1 hour. Bacteria were then pelleted by centrifugation and resuspended in 1X PBS. The  $\text{OD}_{600 \text{ nm}}$  was adjusted to 0.05 using 1X PBS for the fixed *S. pyogenes* bacteria. Then Af488-maleimide dye (5  $\text{mg ml}^{-1}$ ) in DMSO was diluted 100-fold by direct addition to the  $\text{OD}_{600 \text{ nm}} = 0.05$  bacteria solution. The solution was mixed by shaking in the fridge for 12 hours. The bacteria were rinsed thrice by centrifugation (4500 rpm on benchtop centrifuge for 5 minutes) and then resuspended in 1X PBS. An aliquot of 10  $\mu\text{L}$  of the samples was dropped on a glass slide and imaged using dark-field microscopy, epi-fluorescence microscopy, and a 40X objective.

#### 2.6.2.2 Red fluorescent silica@Au NPs staining of fixed *S. pyogenes*.

*Streptococcus pyogenes* was grown in LB media for 16 hours. The bacteria were pelleted and fixed in 4% buffered para-formaldehyde for 1 hour. Bacteria were then pelleted by

centrifugation and resuspended in 1X PBS. The  $\text{OD}_{600 \text{ nm}}$  was adjusted to 0.05 using 1x PBS for the fixed *S. pyogenes* bacteria. Then 1% v/v red fluorescent silica@Au NPs was diluted 5-fold by direct addition to the  $\text{OD}_{600 \text{ nm}} = 0.05$  bacteria solution. The solution was mixed by shaking in the fridge for 12 hours. The bacteria were rinsed thrice by centrifugation (4500 rpm on benchtop centrifuge for 5 minutes) and then resuspended in 1X PBS. An aliquot of 10  $\mu\text{L}$  of the samples were dropped on a glass slide and imaged using dark-field microscopy, epi-fluorescence microscopy, and a 40X objective.

## 2.7 In vivo wound healing studies

Male wild type (C57bl/6) mice (age 6–10 weeks) were prepared with NAIR on the right flank. An aliquot of 100  $\mu\text{l}$  of *Streptococcus pyogenes* strain AP53S+ was injected SubQ with a concentration of  $1\text{--}3 \times 10^8$  CFU per mouse under isoflurane anesthesia. After the wound was established, on day 2, daily measurements were measured and a 100  $\mu\text{l}$  dose of either vehicle, peptide, or nanoparticles with peptide was given topically. The topical dose w.r.t peptide was 150  $\mu\text{M}$ , suspended in 20% w/v Pluronic F-127. After 15 days, the mice were sacrificed. In the second experiment, all the previous steps were followed. The intravenous (IV) dose w.r.t peptide was 100  $\mu\text{M}$ , suspended in 1X PBS. A retro-orbital injection of 100  $\mu\text{l}$  was done with either vehicle, peptide or nanoparticles on day 2 when topical treatment was begun. Wound sizes were recorded daily. The mice were allowed to fully heal before anesthetizing with a rodent cocktail (9 parts ketamine (100  $\text{mg ml}^{-1}$ ) + 9 parts xylazine (20  $\text{mg ml}^{-1}$ ) + 3 parts acepromazine (10  $\text{mg ml}^{-1}$ ) + 79 parts saline), (body weight  $\times 10$ ) – 50  $\mu\text{l} = \mu\text{L}$  per mouse and collection of blood and tissues. All studies were approved by the Institutional Animal Care and Use Committee at the University of Notre Dame and were conducted in accordance with the guidelines of the U.S. Public Health Service Policy for Humane Care and Use of Laboratory Animals. All efforts were made to minimize the suffering of the mice. The wound size data were normalized for the analysis based on the size on day 1. The normalized wound sizes were then averaged for each day, and standard deviations were calculated. After the mice were sacrificed, they were dissected, and tissues and organs were collected and fixed in 4% buffered para-formaldehyde. The histology samples were prepared for H & E staining and Gram-staining. Stained samples were imaged under Swift Binocular Compound Microscope SW350B with SWIFT 1.3 Megapixel Digital Camera for Microscope Eyepiece Mount Windows/Mac to record the images.

### 2.7.1 Inductively coupled plasma-optical emission spectroscopy (ICP-OES) for quantification of nanoparticles present in mice organs post-treatment.

Using a scalpel, a longitudinal piece of each organ was harvested and weighed. Samples weighed between 0.01 g and 0.26 g. After weighing, the samples were added to a centrifuge tube. 500  $\mu\text{l}$  of Aqua Regia (1 : 3 nitric acid : hydrochloric acid) was added to begin digestion. A glass rod was used to break down the sample into small pieces. The samples were allowed to digest for 1–7 days. Samples were diluted to 5% Aqua Regia with purified DI water. Samples were



mixed by vortexing and then filtered through a 1.0  $\mu\text{m}$  Nylon syringe filter before testing. The samples were run on a Perkins Elmer Avio 200 using a 5-point standard curve created from Si, Ag, and Au standards (LabChem). The instrument was blanked using a 5% Aqua Regia and purified DI water solution. The concentrations of elements in each sample were related to the weight of digested samples.

## 3 Results and discussion

### 3.1 Nanoparticle characterization

Our research group has confirmed that the structure of our synthesized nanoparticles resembles naturally occurring bacteriophages, with smaller-sized nanoparticles displaying closer mimicry with bacteriophages.<sup>40</sup> The nanoparticles mimic bacteriophages from the family of Microviridae with 88% similarity. Microviridae are tailless bacteriophages, sized 25–27 nm. To visualize the PhaNPs, TEM analysis was carried out (Fig. 2A and B), revealing that the diameter of  $\text{SiO}_2$  nanoparticle core was  $20.5 \text{ nm} \pm 2.1 \text{ nm}$  (Fig. 2A). Analysis of PhaNP@Syn71 showed a nanoparticle diameter of  $20.2 \pm 2.4 \text{ nm}$  (Fig. 2B), verifying that further synthesis processes (addition of gold nanospheres, silver, and Syn71 peptide) do not alter the base diameter of the nanoparticle silica core. In addition, TEM image analysis of PhaNPs and PhaNP@Syn71 demonstrated the presence of gold NPs on the silica core. EDXS compositional analysis of the PhaNPs (Fig. 2C) revealed the presence of Si, Au and Ag, in agreement with the synthesis process, with ICP-OES measurements (ESI A Table S1†) further confirming the presence of Au on  $\text{SiO}_2$ AuNPs, and Au and Ag on PhaNPs. The concentration of Si was  $3.829 \text{ mg ml}^{-1}$  and  $12.068 \text{ mg ml}^{-1}$  for  $\text{SiO}_2$ AuNPs and

PhaNPs, respectively. The concentration of Au on  $\text{SiO}_2$ AuNPs was  $0.124 \text{ mg ml}^{-1}$ , while the Au and Ag concentrations of PhaNPs were  $0.054 \text{ mg ml}^{-1}$  and  $3.924 \text{ mg ml}^{-1}$ , respectively. This is consistent with the synthesis process, showing similar gold content of  $\text{SiO}_2$ AuNPs and PhaNPs, with the addition of Ag on PhaNPs.

PhaNPs were functionalized with the cysteine terminated Syn71 peptide, chosen from syn-larvacin library created by Ross *et al.*<sup>41</sup> Syn-larvacin-71 is a synthetic, unmodified peptide derived from the active region of the enterocin AS-48-like bacteriocin homologue, ribosomally produced by *Paenibacillus larvae*. It was identified using a homology-based search of the truncated enterocin AS-48 previously identified to exhibit anti-bacterial properties. The 25-mer larvacin AS-48 peptide scaffold was used to create a novel, synthetic peptide library. Rational design techniques hypothesized to increase antibacterial activity were employed on the larvacin peptide scaffold. Briefly, in a stepwise fashion, lysine and tryptophan substitutions were made for aliphatic and short-chain amino acids, hypothesized to increase lipid membrane affinity and penetration, respectively. Through the inversion of hydrophobic amino acids within the helical wheel, amphipathicity was increased, and hypothesized to bind to and disrupt the lipid membrane. In total, 95 peptide variants were designed and deemed the syn-larvacin library. To identify potent peptide variants against *S. pyogenes*, minimal inhibitory concentration (MIC) assays were performed using the syn-larvacin scaffold peptide (Table 1). Following the identification of the MIC, peptide variants were screened at half the concentration to identify peptide variants with increased antibacterial activity. After identifying optimized peptide variants, MIC assays, and minimal bactericidal



Fig. 2 Nanoparticle characterization. (A) (i) TEM image of silica NPs before surface modifications (scale bar = 100 nm) and (ii) the size distribution of silica NPs showing an average diameter of  $20.5 \text{ nm} \pm 2.1 \text{ nm}$ . (B) (i) TEM image of PhaNPs used for Syn71 conjugation (scale bar = 100 nm) and (ii) the size distribution of PhaNPs showing an average diameter of  $20.2 \text{ nm} \pm 2.4 \text{ nm}$ . (C) The energy-dispersive X-ray spectrum (EDXS) of PhaNPs confirmed their elemental composition. Distinct energy peaks for Si ( $K_{\alpha} = 1.740 \text{ keV}$ ), O ( $K_{\alpha} = 0.525 \text{ keV}$ ), Au ( $M_{\alpha} = 2.123 \text{ keV}$ ,  $L_{\alpha} = 9.713 \text{ keV}$ ) and Ag ( $K_{\alpha} = 22.163 \text{ keV}$ ,  $L_{\alpha} = 2.983 \text{ keV}$ ) were detected. Al peak is present due to SEM stub material; Mg, Na and Cl peaks are due to the solvent used (PBS buffer).



concentration assays were performed to evaluate potency. The 25-mer Syn-laravacin-71 was robustly immobilized on PhaNPs by adding a cysteine residue at the N-terminal, and we designated the 26-mer cysteine-modified peptide as Syn71.

DLS analysis was conducted on PhaNPs without the Syn71 peptide and PhaNP@Syn71 peptide-modified nanoparticles. The results showed an average hydrodynamic diameter of the nanoparticles to be  $781.7 \pm 498.5$  nm, indicating that it is possible that the PhaNPs clump in PBS solvent (ESI B Table S2†). PhaNP@Syn71 had an average diameter of  $2582 \pm 641.2$  nm, showing a further increase in hydrodynamic radius compared to PhaNPs. The zeta sizer indicated that the ionic strength of the solvent and the surface modification of nanoparticles play a key role in the hydrodynamic radius of colloidal particles in solution.<sup>52–54</sup> These results indicate the actual behavior of the nanoparticles in the PBS solution. The zeta potential results were  $-16.0$  mV for PhaNPs with a conductivity of  $17.8$  mS cm<sup>-1</sup>, while the zeta potential for PhaNP@Syn71 was  $-8.54$  mV with a conductivity of  $16.8$  mS cm<sup>-1</sup>, indicating a decrease in surface potential when the PhaNPs are modified with Syn71 peptide. Both zeta potential and DLS analyses confirmed the Syn71 peptide addition to the PhaNPs surface, showing the change in zeta potential and the size, which has been demonstrated in previously published works to indicate successful peptide addition to the nanoparticles.<sup>36</sup>

LC-MS analysis on the supernatant of PhaNP@Syn71 revealed that there is no residual Syn71 peptide present in the supernatant (ESI C Fig. S2†), indicating that >99.9% of the peptide added during the synthesis process had been absorbed on the PhaNPs. Change in zeta potential when comparing PhaNPs to PhaNP@Syn71 further verified the chemisorption of Syn71 onto the PhaNPs surface.

### 3.2 Biocompatibility with human skin cell line

Various concentrations of PhaNP@Syn71 (vehicle,  $0.25$   $\mu$ M,  $0.5$   $\mu$ M,  $1$   $\mu$ M,  $2$   $\mu$ M,  $4$   $\mu$ M,  $8$   $\mu$ M,  $16$   $\mu$ M,  $32$   $\mu$ M and  $64$   $\mu$ M) were tested on HaCaT human skin keratinocytes (Fig. 3A) and compared against PhaNPs and free Syn71 peptide. The results showed that the PhaNP@Syn71 had significantly lower cytotoxicity than the free peptide, as well as slightly lower toxicity than PhaNPs, displaying almost no change in cytotoxicity from the vehicle up to relatively high concentrations. Syn71 peptide alone showed significantly increased cytotoxicity above  $8$   $\mu$ M. In addition, the SEM imaging confirmed that PhaNP@Syn71 attaches to the HaCaT cells and does not lyse them (Fig. 3B).

Silica-based materials are highly compatible with human cells<sup>55,56</sup>, with amorphous silica nanoparticles with APTES molecules similar to our designed core nanoparticles have been demonstrated to be biocompatible with human cells.<sup>57</sup> Ag nanoparticles are also considered relatively biocompatible compared to other metallic nanoparticles. Therefore, they have been recommended as a good alternative for antibiotics to eradicate bacterial infections with minimal toxicity to surrounding human cells.<sup>58</sup> Ag nanoparticle cytotoxicity is size-dependent, surface-dependent, and dose-dependent,


with high doses of total Ag concentration being toxic.<sup>59</sup> Our design chose  $5$  nm Au/Ag nanospheres, and the arrangement of the nanospheres on the silica core ensures they are not presented as  $<5$  nm, reducing the probability of the nanoparticles permeabilizing mammalian cells.<sup>40</sup> According to Environmental Protection Agency (EPA), the chronic oral Reference Dose (RfD) is  $250$   $\mu$ g top  $750$   $\mu$ g per person per day.<sup>60</sup> However, our PhaNP@Syn71 exhibits the maximum Ag content of  $171.36$   $\mu$ g per ml, leaving it under the EPA-established safety limits.

Several works have shown that the Minimum Inhibitory Concentration (MIC) of free antibacterial peptides is relatively high for inhibiting the growth of pathogenic bacteria, the MICs being higher than the MIC to affect human cells.<sup>61,62</sup> Therefore, integration of the antibacterial peptides with nanoparticles to decrease their MIC, has been pursued in studies showing that in some cases peptide integration into nanoparticles results in smaller MICs than that of the free peptide, although that wasn't the stated goal of our study.<sup>63,64</sup> A few studies have also indicated that the amino acid sequence plays a key role in the cytocompatibility and biocompatibility of peptide coated NPs.<sup>65,66</sup>

Syn71 peptide exhibits dose-dependent toxicity to human cells at  $>8$   $\mu$ M and mild hemolytic activity at  $8$   $\mu$ M. Our designed PhaNP@Syn71 showed significantly decreased cytotoxicity toward mammalian cells compared to free peptides at the same concentration. At relatively high concentrations ( $64$   $\mu$ M), PhaNP@Syn71 cytotoxicity was at 20%, while the free peptide displayed a cytotoxicity of over 50%. Very low cytotoxicity was displayed at concentrations up to  $8$   $\mu$ M (10%), as the free peptide showed cytotoxicity higher than that of the highest concentration of PhaNP@Syn71, confirming the success of lowering the overall cytotoxicity with the developed nanoparticle-peptide constructs.

**3.2.1 *In vitro* scratch closure assay.** To measure the cell migration in the presence of PhaNP@Syn71, a scratch closure assay was carried out on HaCaT cells (Fig. 3C). As a control, cells in media only and cells with Syn71 peptide only were used, to compare against PhaNP@Syn71. A fixed concentration of  $8$   $\mu$ M of Syn71 peptide as well as PhaNP@Syn71 was tested. The results indicated clear scratch closure in the presence of Syn71 peptide only, while the PhaNP@Syn71 did not promote any cell migration (ESI D Fig. S3†). The cell-compatible chamber slide has positively charged wells to allow the HaCaT cells to attach to the bottom of the well. However, since PhaNP@Syn71 indicated a negative zeta potential, and thus a negative charge, the nanoparticles attached to the bottom of the tissue culture treated well instead of the cells, preventing the negatively charged cells from migrating on to the gap in the slide due to charge-charge repulsion. In addition, the negative charge of the PhaNP@Syn71 prevented the nanoparticles to penetrate the HaCaT cells. The cell migration assay demonstrates that the nanoparticles prevent cell movement on the slide since the cells cannot attach to the bottom of the slide well. The results although contrary to what might be expected for wound healing, did not indicate that the PhaNP@Syn71 will be unsuitable for clearing wound infections *in vivo*.





**Fig. 3** (A) Cytocompatibility of PhaNP@Syn71 on the HaCaT human keratinocyte cell line. PhaNP@Syn71 were cytocompatible at all concentrations tested similar to vehicle only control. Syn71 peptide was cytocompatible to 8 µM only. The average of four replicates for each sample was computed together with standard deviations. (B) SEM images of HaCaT cells incubated with PhaNP@Syn71. This indicated that the HaCaT cells integrity was not hampered by Syn71 or PhaNP@Syn71 at 8 µM concentration w.r.t Syn71. (C) *In vitro* scratch closure assay on HaCaT cells showed no cell migration in the presence of PhaNP@Syn71, while Syn71 peptide only presence, or no treatment group control allowed cell migration and scratch closure. This is because the PhaNP@Syn71 had a net negative charge, which will allow them to coat the positively charged tissue culture treated gap, as a consequence of which the surface charge of the gap becomes negative and repels cells migration. The free peptides are positively charged and do not hinder cell migration. 200 µm scale bar is applicable to all optical images.

### 3.3 Biocidal activity of PhaNP@Syn71 against planktonic *S. pyogenes*

Our designed nanoparticles take advantage of the Ag antibacterial effect coupled with the antibacterial effect of the antimicrobial Syn71 peptide. By alloying Ag onto Au nanospheres, we can minimize the leaching of Ag ions, leading to lower off-target toxicity.<sup>40</sup> Silver and antimicrobial peptide containing PhaNP@Syn71 have successfully shown to inhibit the bacteria growth *in vitro* (Fig. 4A) at concentrations between 4 and 50 µM. In addition, free Syn71 peptide was tested for concentrations 8 µM and 4 µM. The comparison of free Syn71 concentrations with corresponding PhaNP@Syn71 concentrations shows that at both concentrations designed PhaNP@Syn71 has higher antibacterial activity than the free peptide. Maximum 8 µM Syn71 peptide was used since the concentrations above are highly

toxic to mammalian cells. Here, we have shown that the *S. pyogenes* growth is almost fully inhibited by concentrations of 25 µM to 50 µM. PhaNP@Syn71 concentration of 8–10 µM also showed a significant halt on bacterial growth after initial growth. The lowest concentration of 4 µM PhaNP@Syn71 inhibited the bacteria growth up to 50%, showing an immediate constant inhibition from the beginning. The minimum inhibitory concentration of PhaNP@Syn71 was determined to be 8.62 µM with concentration in respect to Syn71 loaded on NPs. Colony Forming Units per ml (CFU per ml) further confirmed that at 50 µM concentration of PhaNP@Syn71 kills the *S. pyogenes* (Table 2). Although other concentrations show some live bacteria still present post-treatment, the live bacteria decreased from  $3.17 \times 10^7$  in the control group to  $3.93 \times 10^6$ , with the lowest number of live bacteria being present in the sample treated with 10 µM PhaNP@Syn71. In the growth curve, 25 µM





**Fig. 4** *In vitro* antibacterial activity of PhaNP@Syn71. (A) *S. pyogenes* growth curve in the presence of various concentrations of PhaNP@Syn71. The average of four replicates for each sample was computed together with standard deviations. The 4 μM and 8 μM Syn71 peptide concentrations inhibited bacterial growth. The PhaNP@Syn71 with 4 μM Syn71 showed 50% inhibition of bacterial growth immediately. Consistent bacterial inhibition occurred at 10 μM Syn71 on PhaNP@Syn71. >25 μM of Syn71 on PhaNP@Syn71 led to 100% bactericidal activity. (B) SEM images of *S. pyogenes* incubated with PhaNP@Syn71 compared to controls. (i) *S. pyogenes* formed classic chain structures. (ii) Syn71 peptide clusters latched onto bacterial structures but bacterial structure stayed intact. (iii) SiO<sub>2</sub>@AuNP were found bound to bacterial membranes in large numbers and interestingly prevented bacterial chain formation. (iv) The introduction of silver dramatically altered the outcome. PhaNPs resulted in no intact bacteria. (v) PhaNP@Syn71 resulted in no intact bacteria and large rafts of nanoparticles.

PhaNP@Syn71 exhibits similar high inhibition as 50 μM PhaNP@Syn71, however, the CFU per ml assay shows live bacteria present post-treatment, meaning that at concentrations lower than 50 μM, the nanoparticles do not completely eradicate viable bacteria. These results are relevant in demonstrating that our designed nanoparticle-peptide constructs inhibit *S. pyogenes* growth at very low concentrations compared to a free peptide. The PhaNP@Syn71 are also completely bactericidal at >25 μM concentration while being cytocompatible to human cells, a concentration at which free Syn71 peptides cannot be utilized due to their high cytotoxicity to human cells beyond 8 μM. For the PhaNP@Syn71, the MIC was 8.62 μM while the cysteine modified Syn71 alone had an MIC of 8 μM.

**3.3.1 Mechanisms of antibacterial activity of PhaNP@Syn71.** Syn71 peptide<sup>41</sup> is a 26 amino acids synthetic antimicrobial peptide with a cationic domain responsible for

**Table 2** CFU per ml assay of *S. pyogenes* antibacterial samples with SiO<sub>2</sub>@AuNPs, PhaNPs and various concentrations of PhaNP@Syn71, compared to *S. pyogenes* control was carried out by growing the bacteria collected from the growth measurement samples on an LB agar plate at 37 °C for 16 h

ID	CFU per ml
<i>S. pyogenes</i>	$3.17 \times 10^7 \pm 5.69 \times 10^6$
<i>S. pyogenes</i> + SiO <sub>2</sub> AuNP	$8.93 \times 10^6 \pm 9.45 \times 10^5$
<i>S. pyogenes</i> + PhaNPs	$5.13 \times 10^6 \pm 5.13 \times 10^5$
<i>S. pyogenes</i> + PhaNP@Syn71 (50 μM)	0
<i>S. pyogenes</i> + PhaNP@Syn71 (25 μM)	$5.13 \times 10^6 \pm 1.53 \times 10^5$
<i>S. pyogenes</i> + PhaNP@Syn71 (10 μM)	$3.93 \times 10^6 \pm 1.36 \times 10^6$
<i>S. pyogenes</i> + PhaNP@Syn71 (8 μM)	$4.53 \times 10^6 \pm 4.04 \times 10^5$
<i>S. pyogenes</i> + PhaNP@Syn71 (4 μM)	$4.27 \times 10^6 \pm 2.31 \times 10^5$



antimicrobial activity. The structure of the peptide is a random coil, adopting a helical structure in contact with the bacterial membrane. The positive charge of the amphiphilic Syn71 peptide allows its interaction with negatively charged bacterial membrane, leading to membrane disruption, and consecutively to bacterial growth inhibition or bacterial death. Our design poses a potential synergistic effect of Ag and antimicrobial peptide Syn71, allowing the nanoparticles to attach to the bacteria surface *via* positively charged peptide residues, that assume a helical structure on contact with the bacterial membrane and puncturing the membrane, allowing the nanoparticles to prolong their interaction with the bacteria, which further disrupts the bacterial processes such as bacterial cell wall integrity and bacterial division.

SEM imaging was used to visualize the attachment of nanoparticles onto the bacterial cell membrane as well as the further internalization of the nanoparticles inside the bacteria cells (Fig. 4B). *S. pyogenes* bacteria form chain-like structures in their natural environment. The analysis of the SEM images confirmed the round coccus shape and formation of chain-like structures of untreated *S. pyogenes* (Fig. 4B(i)). It has been previously shown that enterocin AS-48 and AS-48-like antimicrobial peptides act *via* their interaction with and disruption of *S. pyogenes* membrane.<sup>41,67</sup> In this case, the Syn71 peptide formed microclusters on the bacteria and punctured the bacterial cell wall, confirming the previously studied effect of the peptide on the bacteria (Fig. 4B(ii)). PhaNPs with Au but without Ag and peptide showed binding to the bacteria surface, this way disrupting the bacterial chain formation (Fig. 4B(iii)). In contrast, PhaNPs with Ag but without the peptide exhibited significant bacterial lysis due to antibacterial properties of Ag (Fig. 4B(iv)).<sup>2</sup> PhaNP@Syn71 nanoparticles exhibited rapid lysis of bacteria, leading to complete destruction of the bacterial structure with no viable bacteria present in the sample, and only PhaNP@Syn71 were observed on SEM images (Fig. 4B(v)), showing that our designed nanoparticles can eradicate the *S. pyogenes* from a given site.

Additionally, maleimide dyes were utilized to selectively block the thiol on bacteria to test to see if thiol residues were the primary points of adhesion of PhaNPs (sans peptide and silver) to bacteria (ESI E Fig. S4†). We synthesized fluorescent PhaNPs(Ag(-)peptide(-)) by volume-labelling the silica core with rhodamine using techniques previously developed in our laboratory to track the PhaNPs interaction with bacteria utilizing fluorescence microscopy.<sup>68–72</sup> The blocking of thiol residues on the bacterial surface did not hinder the ability of PhaNPs to disrupt the chain forming ability of the bacteria. The results (ESI E Fig. S4†) indicated that PhaNPs(Ag(-)peptide(-)) can bind to bacteria by targeting surface thiols, reducing disulfide bridges to thiols, and bind to amine rich peptide sequences used by the bacteria for forming chain like structures.<sup>73–75</sup>

**3.3.2 Testing for evolution of resistance by *S. pyogenes* to PhaNP@Syn71.** After >1000 generations of *S. pyogenes* (28 days of culture) were exposed to three different sub-MIC concentrations of PhaNP@Syn71 (0.1MIC, 0.2MIC, 0.35MIC), there was an emergence of resistance for the *S. pyogenes*, which were constantly exposed to the lower two sub-MIC concentrations of

PhaNP@Syn71. MICs of the bacteria growing in the 0.1MIC concentrations for PhaNP@Syn71 were double or slightly higher than the MICs of the control populations. For the PhaNP@Syn71 control population, the 0.5MIC was 3.109  $\mu\text{M}$ , with a MIC of 5.596  $\mu\text{M}$ , while the population grown in the 0.1MIC concentration for 28 days had a 0.5MIC of 8.117  $\mu\text{M}$  (2.6-fold higher) and a MIC of 18.038  $\mu\text{M}$  (3-fold higher). The populations grown in the 0.2MIC concentration for the PhaNP@Syn71 had slightly higher MICs than the controls. Compared to the controls above, the 0.5MIC for the population grown in the 0.2MIC concentration of PhaNP@Syn71 for 28 days was 5.517  $\mu\text{M}$  (1.8-fold higher), while the MIC was 9.931  $\mu\text{M}$  (1.8-fold higher). This slight resistance observed could be due to the nanoparticles of the lower concentrations not exhibiting the full inhibitory effect on the *S. pyogenes* bacteria. However, the population of bacteria exposed to 0.35MIC concentration of PhaNP@Syn71 for 28 days showed no signs of evolved resistance thus highlighting the need for proper dosage to be used consistently when treating an infection site with PhaNP@Syn71. Traditionally, antibacterial dosages are significantly higher than the MIC. We in fact utilized 20X MIC for the *in vivo* intravenous dosage and for the topical treatment dosage *in vivo* because of the high cytocompatibility and biocompatibility of our PhaNP@Syn71, which will further negate the emergence of resistance based on the evolution of resistance results.

### 3.4 *In vivo* testing on mouse wound infection healing model

The antibacterial effect of PhaNP@Syn71 was tested *in vivo* on male wild type (C57bl/6) mouse ( $n = 3-4$ ) using a *Streptococcus pyogenes* wound healing model which was approved by the University of Notre Dame's Institutional Animal Care and Use Committee. To introduce the infection, the *S. pyogenes* strain AP53S+ was injected into the right flank of the mouse subcutaneously (SubQ). On day 2 after the infection, a wound had established, and treatment was begun with two treatment variants: topical application only or a combination of intravenous (IV) injection and topical application.

Topical-only treatment of the infected wounds with PhaNP@Syn71 indicated clear stabilization of the wound size (ESI F Fig. S5†), while the vehicle-only and Syn71 peptide-only treatment exhibited an initial increase in the wound size, indicating irritation of the wound. By day 9 the wound had decreased to half of the initial size and fully healed by the end of the treatment course (day 17) with PhaNP@Syn71 topical only treatment. The number of mice with wounds decreased from the initial four to three by day 11 (ESI F Fig. S5†). By day 15, it further decreased to two mice with wounds and by the end of the treatment period (day 17), half of the infected mice had been healed. At the end of the treatment period (day 17), the wound treated with PhaNP@Syn71 was fully healed, while the control and Syn71 peptide-only treatments still showed the presence of a wound (ESI F Fig. S5†).

The combination of the one-time IV injection on day 2 and further daily topical treatment was carried out using vehicle only for both IV and topical (VV), peptide only for both (PP), peptide only for IV in combination with PhaNP@Syn71 topical



(NP), and PhaNP@Syn71 only for both IV and topical (NN). The combination of Syn71 peptide IV injections with PhaNP@Syn71 topical treatment resulted in an initial small increase in the wound size, similar to the vehicle-only and Syn71 peptide-only treatments, while PhaNP@Syn71 IV injection combined with PhaNP@Syn71 daily topical treatment of the infected wounds confirmed the initial stabilization of the wound size (Fig. 5A). The latter treatment method resulted in the wound size decreasing to half of the initial wound size by day 8, and wounds being fully healed by day 17. The number of mice with wounds decreased from the initial four to three by day 15 (Fig. 5B). By day 17 there were no mice with wounds present, indicating all mice were healed.

Hematoxylin and Eosin (H & E) staining of the dissected organs and skin tissue (Fig. 6A) was carried out by a pathologist to score post-treatment inflammation. There was no significant abnormal inflammation noted. Inflammation was present on skin tissue with the wound for all treatment groups. However, this is a natural occurrence due to the presence of macrophages clearing the bacteria and debris while also releasing cytokines necessary for wound healing and tissue remodeling. In mice treated with Syn71 peptide only IV injection and topical application, and the combination of Syn71 peptide IV injection and PhaNP@Syn71, there was some inflammation noted in the lungs. No additional inflammation of organs was observed in mice treated with the combination of IV injection and topical application using PhaNP@Syn71 treatment. SEM analysis of the skin tissue was carried out (ESI F Fig. S7†) confirming the histology results. Some inflammation was observed, consistent with the histology analysis, since the infected wound disrupted the tissues and created an immune response leading to inflammation. However, there were also many hair follicles present, indicating tissue regeneration.

Although there was mild inflammation in the skin tissue due to the wound infection, the histology samples of mice treated with PhaNP@Syn71 did not show increased inflammation of any of the organs, proving that our nanoparticle design is biocompatible, and does not result in the accumulation of nanoparticles in organs. The Gram-staining of the skin tissue wounds (Fig. 6B) indicated no bacteria present in the wound after the end of the treatment period (day 17). Therefore, PhaNP@Syn71 fully eradicated the bacteria cells within the treatment period. *In vivo* results indicate that PhaNP@Syn71 topical treatment, as well as the combination of the IV injection and topical treatment, immediately stabilizes the infected wound, while the control and Syn71 peptide-only treatment led to a progression in wound size before the animal's natural immunity stabilizes the wound. This proves the PhaNP@Syn71 design is highly effective in immediately stopping wound growth and in clearing infection.

ICP-OES analysis was carried out on dissected organs and tissues to quantify the elements from nanoparticles (*i.e.*, Si, Au and Ag) present in the organs post-treatment, indicating how much nanoparticles were retained in different organs and tissues (see ESI G Tables S3–S6†). The results were given in mg of elements per 1 g of organ/tissue. In any of the treatment options (VV, PP, NP and NN), there was no Ag present, which




Fig. 5 *In vivo* mouse wound model experiments with a combinatory treatment of one intravenous (IV) injection (100  $\mu$ M w.r.t Syn71) followed by a daily topical dose of PhaNP@Syn71 (150  $\mu$ M w.r.t Syn71). (A) Normalized wound healing size in mice treated with PhaNP@Syn71 vs. controls. (B) Number of mice with wounds throughout the treatment. The PhaNP@Syn71 did not seem to increase the rate of wound healing in comparison to the controls, but it immediately stabilized the wound size and prevented it from increasing in size from the first dosage application. Abbreviation's key: pluronic control (VV = IV + topical), peptide control (PP = IV + topical), peptide IV + PhaNP@Syn71 topical (NP) and PhaNP@Syn71 (NN = IV + topical).

would indicate Ag being cleared out or being below the limits of detection of the analytical instrument ( $5 \mu\text{g L}^{-1}$  or 5 ppb). It was observed that there is a higher amount of Si present in the lungs, spleen, and fecal pellet post-treatment. It has been shown previously that silica nanoparticles mainly accumulate in the spleen, liver, and lungs due to endocytosis by macrophages.<sup>76</sup> They get trapped in the lungs due to passive entrapment in the endothelium opening of the liver and spleen or in pulmonary capillaries since the reticuloendothelial system internalizes silica nanoparticles after sequestration in the liver and spleen.<sup>77</sup> The accumulation of Si in fecal pellets indicates that the clearance of the nanoparticles is *via* the GI tract due to their degradation in the liver and spleen.<sup>78</sup> The Au particles have mainly accumulated in the lungs, spleen and heart. However, as






Fig. 6 Histology samples of mice organs and skin tissue. (A) H & E staining on mouse organs and skin tissue was analyzed and scored for inflammation by a board-certified pathologist. The results showed no damaging inflammation of the organs in any of the mice. Skin tissue showed signs of inflammation from the wound infection. Abbreviations: VV – vehicle (IV + topical), PP – peptide (IV + topical), NP – peptide (IV) + PhaNP@Syn71 (topical), NN – PhaNP@Syn71 (IV + topical). (B) Serial staining of histology sections of skins by H & E and Gram staining did not reveal any bacterial colonies in the subcutaneous skin sections at the endpoint. Hair growth in the wound indicated wound healing. Histology sections were imaged at 10 $\times$  magnification.

noted before there was no inflammation of any organs due to the PhaNP@Syn71. It was noted that there is a higher accumulation of Si and Au in the NP treatment group but these are classified as GRAS compounds (Generally Regarded as Safe) by the FDA due to their approved use in pharmaceuticals as fillers.<sup>79</sup>

## 4 Conclusions

In this study, we have successfully demonstrated that our modular design of phage-mimicking nanoparticles (PhaNPs) modified with antimicrobial peptide Syn71 (PhaNP@Syn71) has high antibacterial activity while exhibiting a low cytotoxic effect on mammalian cells. The biocompatibility tests on HaCaT cells exhibited significantly lower cytotoxicity to the cells (at least 8-fold) than that of the corresponding concentrations of free Syn71 peptide. In addition, PhaNP@Syn71 obtained stably low cytotoxicity up to higher concentrations, with the highest concentration (64  $\mu$ M) of the PhaNP@Syn71 exhibiting cytotoxicity no higher than the vehicle-only control. Regarding the antibacterial effect of PhaNP@Syn71, they significantly inhibit the growth of *Streptococcus pyogenes* at concentrations as low as

10  $\mu$ M and completely kill the bacteria at concentrations >25  $\mu$ M. *S. pyogenes* does not achieve its maximum growth potential at any of the PhaNP@Syn71 concentrations tested (4  $\mu$ M to 64  $\mu$ M). At equivalent concentrations, PhaNP@Syn71 displayed stronger antibacterial activity than that of its corresponding concentrations of the free Syn71 peptide. SEM analysis to study the mechanisms of action for the antibacterial effect of PhaNP@Syn71 revealed that the PhaNP@Syn71 had attached to *S. pyogenes* cell wall, lysing the cell and therefore inhibiting its growth and killing it since no bacterial cells were observed on SEM images when incubated with PhaNP@Syn71.

PhaNP@Syn71 showed a significant ability to improve the infection treatment outcome in the *in vivo* mouse wound healing model, and immediately stabilized the *S. pyogenes* induced wound size from day 1 through the treatment period of 15–17 days. Further histological analysis displayed mild inflammation in skin tissues, while no inflammation was observed in any of the organs, indicating that the PhaNP@Syn71 design is biocompatible. While analyzing the post-treatment accumulation of the nanoparticles, it was shown that the nanoparticles tend to accumulate in the lungs, spleen and large intestines.



Therefore, these data show that the post-treatment clearance of the PhaNP@Syn71 occurs primarily *via* the GI tract.

The MIC of PhaNP@Syn71 to *S. pyogenes* was 8.62  $\mu\text{M}$ , which was slightly higher than the MIC of cysteine-modified Syn71 peptide alone, which was 8  $\mu\text{M}$ . But the cytocompatibility of Syn71 on PhaNP@Syn71 was approximately an order of magnitude higher than the Syn71 peptide alone. The increase range of cytocompatible doses allowed us to test previously untestable concentrations of Syn71 for bactericidal activity without cause for concern of increasing toxicity to human cells. The evolution of resistance study also indicated the absence of resistance after more than 1000 generations of *S. pyogenes* were exposed to 0.35X MIC (sub-MIC) of PhaNP@Syn71 which is highly significant for the long-term use of PhaNP@Syn71 as an alternate to antibiotics. The therapeutic dose used to treat wound infection was 20X MIC of PhaNP@Syn1 to *S. pyogenes*.

In conclusion, the results of this study demonstrate that the PhaNP@Syn71 design exhibits high antibacterial activity towards *S. pyogenes* infections while exhibiting higher biocompatibility with mammalian cells than the free Syn71 peptide, without promoting emergence of resistant bacterial strains when utilized at the appropriate concentration range. This study therefore, lays a foundation for a novel antibiotic-free nanoparticle system to clear bacterial infections with low side-effects, through multiple doses without promoting the emergence of resistant strains of bacteria. This study has demonstrated that PhaNP@Syn71 design will be a key component in the fight against the emergence and spread of antimicrobial resistant strains of bacteria.

## Author contributions

Conceptualization: Nallathamby, P. D., Lee, S., Castellino, F., Ploplis, V., Donahue, D.; data curation: Olesk, J., Donahue, D., Ross, J., Hopf, J., Sheehan, C., Armknecht, K., Bennett, Z., and Nallathamby, P. D.; formal analysis: Olesk, J., Donahue, D., Ross, J., Bennett, Z., and Nallathamby, P. D.; funding acquisition: Nallathamby, P. D., Ploplis, V., Castellino, F., and Lee, S.; investigation: Olesk, J., Donahue, D., Ross, J., Kudary, C., Hopf, J., Sheehan, C., Armknecht, K., and Bennett, Z.; methodology: Hopf, J., Donahue, D., Ross, J., and Nallathamby, P. D.; project administration: Nallathamby, P. D.; resources: Lee, S., Ploplis, V., Castellino, F., and Nallathamby, P. D.; supervision: Nallathamby, P. D., and Kudary, C.; validation: Nallathamby, P. D.; visualization: Bennett, Z., Olesk, J., Donahue, D., and Nallathamby, P. D.; writing – original draft: Olesk, J., and Nallathamby, P. D.; writing – review & editing: Donahue, D., Ross, J., Lee, S., Ploplis, V., Castellino, F., and Nallathamby, P. D.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The Nallathamby lab would like to acknowledge the financial and material support of the Notre Dame Berthiaume Institute

for Precision Health (BIPH), and the Notre Dame Centre for Nano Science and Technology's (NDNano) undergraduate summer research fellowships (NURF). We thank the staff of the Materials Characterization Facility, ASEND facility, CEST-ND, Freimann Life Sciences Center, technician at the Berthiaume Institute for Precision Health, and the Notre Dame Integrated Imaging Facility for analytical services. ICP-OES measurements were performed on a PerkinElmer Optima 8000 in the Center for Environmental Science and Technology at the University of Notre Dame. Conor Sheehan, Kevin Armknecht and Zachary Bennett were undergraduate research associates. Conor Sheehan (NURF'22) and Kevin Armknecht (NURF'23) had NDNano undergraduate summer research fellowships. Johanna Olesk was funded by the Notre Dame (ND) Energy Materials Science and Engineering Fellowship. The research was supported by a Project Development Team grant from the Indiana Clinical and Translational Sciences Institute (CTSI-PDT: 373037-31005-FY19CTSIK), Institutional Research Grants from the American Cancer Society (ACS IRG-17-182-04, ACS IRG-17-182-04-2) and seed grants from the Notre Dame Berthiaume Institute for Precision Health (372333-31025) and (372717-43310-FY17RFP).

## References

- 1 S. S. Ahmed, K. E. Diebold, J. M. Brandvold, S. S. Ewaidah, S. Black, A. Ogundimu, Z. Li, N. D. Stone and C. A. Van Beneden, The role of wound care in 2 group A streptococcal outbreaks in a Chicago skilled nursing facility 2015–2016, *Open Forum Infect. Dis.*, 2018, 5, ofy145.
- 2 M. Deutscher, S. Schillie, C. Gould, J. Baumbach, M. Mueller, C. Avery and C. A. Van Beneden, Investigation of a group A streptococcal outbreak among residents of a long-term acute care hospital, *Clin. Infect. Dis.*, 2011, 52(8), 988–994.
- 3 S. A. Nanduri, B. J. Metcalf, M. A. Arwady, C. Edens, M. A. Lavin, J. Morgan, W. Clegg, A. Beron, J. P. Albertson, R. Link-Gelles, *et al.*, Prolonged and large outbreak of invasive group A Streptococcus disease within a nursing home: repeated intrafacility transmission of a single strain, *Clin. Microbiol. Infect.*, 2019, 25(2), 248.e1–248.e7.
- 4 K. Fay, J. Onukwube, S. Chochua, W. Schaffner, P. Cieslak, R. Lynfield, A. Muse, C. Smelser, L. H. Harrison, M. Farley, *et al.*, Patterns of antibiotic nonsusceptibility among invasive group A Streptococcus infections—United States, 2006–2017, *Clin. Infect. Dis.*, 2021, 73(11), 1957–1964.
- 5 J. Ibrahim, J. A. Eisen, G. Jospin, D. A. Coil, G. Khazen and S. Tokajian, Genome analysis of Streptococcus pyogenes associated with pharyngitis and skin infections, *PLoS One*, 2016, 11(12), e0168177.
- 6 S. Kanwal and P. Vaitla, *Streptococcus Pyogenes*, StatPearls, 2023.
- 7 M. K. Siggins, N. N. Lynskey, L. E. Lamb, L. A. Johnson, K. K. Huse, M. Pearson, S. Banerji, C. E. Turner, K. Woollard, D. G. Jackson, *et al.*, Extracellular bacterial lymphatic metastasis drives Streptococcus pyogenes systemic infection, *Nat. Commun.*, 2020, 11(1), 1–12.
- 8 Y. Li, J. Rivers, S. Mathis, Z. Li, S. Velusamy, S. A. Nanduri, C. A. Van Beneden, P. Snippes-Vagnone, R. Lynfield,



- L. McGee, *et al.*, Genomic surveillance of *Streptococcus pyogenes* strains causing invasive disease, United States, 2016–2017, *Front. Microbiol.*, 2020, **11**, 1547.
- 9 L. Zhu, R. J. Olsen, W. Nasser, I. Riva Morales and J. M. Musser, Trading capsule for increased cytotoxin production: contribution to virulence of a newly emerged clade of emm89 *Streptococcus pyogenes*, *mBio*, 2015, **6**(5), e01378.
- 10 W. C. Albrich, D. L. Monnet and S. Harbarth, Antibiotic selection pressure and resistance in *Streptococcus pneumoniae* and *Streptococcus pyogenes*, *Emerging Infect. Dis.*, 2004, **10**(3), 514.
- 11 M. J. Bottery, J. W. Pitchford and V. P. Friman, Ecology and evolution of antimicrobial resistance in bacterial communities, *ISME J.*, 2021, **15**(4), 939–948, DOI: [10.1038/s41396-020-00832-7](https://doi.org/10.1038/s41396-020-00832-7).
- 12 A. F. Johnson and C. N. LaRock, Antibiotic treatment, mechanisms for failure, and adjunctive therapies for infections by group A *Streptococcus*, *Front. Microbiol.*, 2021, **12**, 760255.
- 13 P. Makvandi, C.-Y. Wang, E. N. Zare, A. Borzacchiello, L.-N. Niu and F. R. Tay, Metal-based nanomaterials in biomedical applications: antimicrobial activity and cytotoxicity aspects, *Adv. Funct. Mater.*, 2020, **30**(22), 1910021.
- 14 J. M. Munita and C. A. Arias, Mechanisms of antibiotic resistance, *Microbiol. Spectr.*, 2016, **4**(2), 0016.
- 15 V. Cattoir, Mechanisms of *Streptococcus pyogenes* Antibiotic Resistance, *Streptococcus pyogenes: Basic Biology to Clinical Manifestations*, 2nd edn, 2022, ch. 30.
- 16 D. Passàli, M. Lauriello, G. C. Passàli, F. M. Passàli and L. Bellussi, Group A streptococcus and its antibiotic resistance, *Acta Otorhinolaryngol. Ital.*, 2007, **27**(1), 27.
- 17 M. Gakiya-Teruya, L. Palomino-Marcelo, S. Pierce, A. M. Angeles-Boza, V. Krishna and J. C. F. Rodriguez-Reyes, Enhanced antimicrobial activity of silver nanoparticles conjugated with synthetic peptide by click chemistry, *J. Nanopart. Res.*, 2020, **22**(4), 1–11.
- 18 A. Gupta, R. F. Landis, C.-H. Li, M. Schnurr, R. Das, Y.-W. Lee, M. Yazdani, Y. Liu, A. Kozlova and V. M. Rotello, Engineered polymer nanoparticles with unprecedented antimicrobial efficacy and therapeutic indices against multidrug-resistant bacteria and biofilms, *J. Am. Chem. Soc.*, 2018, **140**(38), 12137–12143.
- 19 J. S. Kim, K. N. Yu, J.-H. Kim, S. J. Park, H. J. Lee, S. H. Kim, Y. K. Park, Y. H. Park, C.-Y. Hwang, *et al.*, Antimicrobial effects of silver nanoparticles, *Nanomed. Nanotechnol. Biol. Med.*, 2007, **3**(1), 95–101.
- 20 J. Li, W. Sun, Z. Yang, G. Gao, H.-H. Ran, K.-F. Xu, Q.-Y. Duan, X. Liu and F.-G. Wu, Rational design of self-assembled cationic porphyrin-based nanoparticles for efficient photodynamic inactivation of bacteria, *ACS Appl. Mater. Interfaces*, 2020, **12**(49), 54378–54386.
- 21 C. A. Marangon, V. C. A. Martins, M. H. Ling, C. C. Melo, A. M. G. Plepis, R. L. Meyer and M. Nitschke, Combination of rhamnolipid and chitosan in nanoparticles boosts their antimicrobial efficacy, *ACS Appl. Mater. Interfaces*, 2020, **12**(5), 5488–5499.
- 22 P. D. Nallathamby, K. J. Lee, T. Desai and X. H. Xu, Study of the multidrug membrane transporter of single living *Pseudomonas aeruginosa* cells using size-dependent plasmonic nanoparticle optical probes, *Biochemistry*, 2010, **49**(28), 5942–5953, DOI: [10.1021/bi100268k](https://doi.org/10.1021/bi100268k).
- 23 S. M. Dizaj, F. Lotfipour, M. Barzegar-Jalali, M. H. Zarrintan and K. Adibkia, Antimicrobial activity of the metals and metal oxide nanoparticles, *Mater. Sci. Eng. C*, 2014, **44**, 278–284.
- 24 M. A. Ansari, H. M. Khan, A. A. Khan, M. K. Ahmad, A. A. Mahdi, R. Pal and S. S. Cameotra, Interaction of silver nanoparticles with *Escherichia coli* and their cell envelope biomolecules, *J. Basic Microbiol.*, 2014, **54**(9), 905–915.
- 25 P. Jena, M. Bhattacharya, G. Bhattacharjee, B. Satpati, P. Mukherjee, D. Senapati and R. Srinivasan, Bimetallic gold-silver nanoparticles mediate bacterial killing by disrupting the actin cytoskeleton MreB, *Nanoscale*, 2020, **12**(6), 3731–3749.
- 26 T. Bruna, F. Maldonado-Bravo, P. Jara and N. Caro, Silver nanoparticles and their antibacterial applications, *Int. J. Mol. Sci.*, 2021, **22**(13), 7202.
- 27 G. Zhao and S. E. Stevens, Multiple parameters for the comprehensive evaluation of the susceptibility of *Escherichia coli* to the silver ion, *BioMetals*, 1998, **11**, 27–32.
- 28 A. Ivask, A. ElBadawy, C. Kaweteerawat, D. Boren, H. Fischer, Z. Ji, C. H. Chang, R. Liu, T. Tolaymat, D. Telesca, *et al.*, Toxicity mechanisms in *Escherichia coli* vary for silver nanoparticles and differ from ionic silver, *ACS Nano*, 2014, **8**(1), 374–386.
- 29 A. Salleh, R. Naomi, N. D. Utami, A. W. Mohammad, E. Mahmoudi, N. Mustafa and M. B. Fauzi, The potential of silver nanoparticles for antiviral and antibacterial applications: a mechanism of action, *Nanomaterials*, 2020, **10**(8), 1566.
- 30 S. S. I. Abdalla, H. Katas, J. Y. Chan, P. Ganasan, F. Azmi and M. F. M. Busra, Antimicrobial activity of multifaceted lactoferrin or graphene oxide functionalized silver nanocomposites biosynthesized using mushroom waste and chitosan, *RSC Adv.*, 2020, **10**(9), 4969–4983.
- 31 O. Choi, C.-P. Yu, G. E. Fernández and Z. Hu, Interactions of nanosilver with *Escherichia coli* cells in planktonic and biofilm cultures, *Water Res.*, 2010, **44**(20), 6095–6103.
- 32 P. V. AshaRani, G. Low Kah Mun, M. P. Hande and S. Valiyaveetil, Cytotoxicity and genotoxicity of silver nanoparticles in human cells, *ACS Nano*, 2009, **3**(2), 279–290.
- 33 P. D. Nallathamby and X. H. Xu, Study of cytotoxic and therapeutic effects of stable and purified silver nanoparticles on tumor cells, *Nanoscale*, 2010, **2**(6), 942–952, DOI: [10.1039/c0nr00080a](https://doi.org/10.1039/c0nr00080a).
- 34 B. Casciaro, M. Moros, S. Rivera-Fernandez, A. Bellelli, J. M. Fuente and M. L. Mangoni, Gold-nanoparticles coated with the antimicrobial peptide esculentin-1a (1-21) NH<sub>2</sub> as a reliable strategy for antipseudomonal drugs, *Acta Biomater.*, 2017, **47**, 170–181.



- 35 J. Gao, H. Na, R. Zhong, M. Yuan, J. Guo, L. Zhao, Y. Wang, L. Wang and F. Zhang, One step synthesis of antimicrobial peptide protected silver nanoparticles: the core-shell mutual enhancement of antibacterial activity, *Colloids Surf., B*, 2020, **186**, 110704.
- 36 W. Li, Y. Li, P. Sun, N. Zhang, Y. Zhao, S. Qin and Y. Zhao, Antimicrobial peptide-modified silver nanoparticles for enhancing the antibacterial efficacy, *RSC Adv.*, 2020, **10**(64), 38746–38754.
- 37 S. Srivastava, K. Dashora, K. L. Ameta, N. P. Singh, H. A. El-Enshasy, M. C. Pagano, A. E.-L. Hesham, G. D. Sharma, M. Sharma and A. Bhargava, Cysteine-rich antimicrobial peptides from plants: the future of antimicrobial therapy, *Phytother. Res.*, 2021, **35**(1), 256–277.
- 38 L. Wang, C. Hu and L. Shao, The antimicrobial activity of nanoparticles: present situation and prospects for the future, *Int. J. Nanomed.*, 2017, **12**, 1227.
- 39 S. Ruden, K. Hilpert, M. Berditsch, P. Wadhvani and A. S. Ulrich, Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides, *Antimicrob. Agents Chemother.*, 2009, **53**(8), 3538–3540.
- 40 J. Hopf, M. Waters, V. Kalwajtyts, K. E. Carothers, R. K. Roeder, J. D. Shrout, S. W. Lee and P. D. Nallathamby, Phage-mimicking antibacterial core-shell nanoparticles, *Nanoscale Adv.*, 2019, **1**(12), 4812–4826.
- 41 J. N. Ross, F. R. Fields, V. R. Kalwajtyts, A. J. Gonzalez, S. O'Connor, A. Zhang, T. E. Moran, D. E. Hammers, K. E. Carothers and S. W. Lee, Synthetic peptide libraries designed from a minimal alpha-helical domain of AS-48-bacteriocin homologs exhibit potent antibacterial activity, *Front. Microbiol.*, 2020, **11**, 589666.
- 42 E. M. Windels, J. E. Michiels, M. Fauvart, T. Wenseleers, B. Bergh and J. Michiels, Bacterial persistence promotes the evolution of antibiotic resistance by increasing survival and mutation rates, *ISME J.*, 2019, **13**(5), 1239–1251.
- 43 S. T. Gentry, S. J. Fredericks and R. Krchnavek, Controlled particle growth of silver sols through the use of hydroquinone as a selective reducing agent, *Langmuir*, 2009, **25**(5), 2613–2621.
- 44 T. Huang, P. D. Nallathamby and X. H. Xu, Photostable single-molecule nanoparticle optical biosensors for real-time sensing of single cytokine molecules and their binding reactions, *J. Am. Chem. Soc.*, 2008, **130**(50), 17095–17105, DOI: [10.1021/ja8068853](https://doi.org/10.1021/ja8068853).
- 45 T. Huang, P. D. Nallathamby, D. Gillet and X. H. Xu, Design and synthesis of single-nanoparticle optical biosensors for imaging and characterization of single receptor molecules on single living cells, *Anal. Chem.*, 2007, **79**(20), 7708–7718, DOI: [10.1021/ac0709706](https://doi.org/10.1021/ac0709706).
- 46 Y. Xue, X. Li, H. Li and W. Zhang, Quantifying thiol-gold interactions towards the efficient strength control, *Nat. Commun.*, 2014, **5**, 4348, DOI: [10.1038/ncomms5348](https://doi.org/10.1038/ncomms5348).
- 47 Y. Lyu, L. M. Becerril, M. Vanzan, S. Corni, M. Cattelan, G. Granozzi, M. Frascioni, P. Rajak, P. Banerjee, R. Ciancio, *et al.*, The Interaction of Amines with Gold Nanoparticles, *Adv. Mater.*, 2023, e2211624, DOI: [10.1002/adma.202211624](https://doi.org/10.1002/adma.202211624).
- 48 C.-C. Liang, A. Y. Park and J.-L. Guan, *In vitro* scratch assay: a convenient and inexpensive method for analysis of cell migration *in vitro*, *Nat. Protoc.*, 2007, **2**(2), 329–333.
- 49 R. Humphries, A. M. Bobenchik, J. A. Hindler and A. N. Schuetz, Overview of Changes to the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, M100, 31st Edition, *J. Clin. Microbiol.*, 2021, **59**(12), e0021321, DOI: [10.1128/JCM.00213-21](https://doi.org/10.1128/JCM.00213-21).
- 50 R. Vinchhi, C. Jena and N. Matange, Adaptive laboratory evolution of antimicrobial resistance in bacteria for genetic and phenotypic analyses, *STAR Protoc.*, 2023, **4**(1), 102005, DOI: [10.1016/j.xpro.2022.102005](https://doi.org/10.1016/j.xpro.2022.102005).
- 51 M. Lagator, H. Uecker and P. Neve, Adaptation at different points along antibiotic concentration gradients, *Biol. Lett.*, 2021, **17**(5), 20200913, DOI: [10.1098/rsbl.2020.0913](https://doi.org/10.1098/rsbl.2020.0913).
- 52 T. L. McGinnity, V. Sokolova, O. Prymak, P. D. Nallathamby, M. Epple and R. K. Roeder, Colloidal stability, cytotoxicity, and cellular uptake of HfO<sub>2</sub> nanoparticles, *J. Biomed. Mater. Res., Part B*, 2021, **109**(10), 1407–1417.
- 53 K. Suttiponparnit, J. Jiang, M. Sahu, S. Suvachittanont, T. Charinpanitkul and P. Biswas, Role of Surface Area, Primary Particle Size, and Crystal Phase on Titanium Dioxide Nanoparticle Dispersion Properties, *Nanoscale Res. Lett.*, 2010, **6**(1), 27, DOI: [10.1007/s11671-010-9772-1](https://doi.org/10.1007/s11671-010-9772-1).
- 54 D. S. Nikam, S. V. Jadhav, V. M. Khot, R. S. Ningthoujam, C. K. Hong, S. S. Mali and S. H. Pawar, Colloidal stability of polyethylene glycol functionalized Co<sub>0.5</sub>Zn<sub>0.5</sub>Fe<sub>2</sub>O<sub>4</sub> nanoparticles: effect of pH, sample and salt concentration for hyperthermia application, *RSC Adv.*, 2014, **4**(25), 12662–12671, DOI: [10.1039/C3RA47319H](https://doi.org/10.1039/C3RA47319H).
- 55 H. Jaganathan and B. Godin, Biocompatibility assessment of Si-based nano- and micro-particles, *Adv. Drug Delivery Rev.*, 2012, **64**(15), 1800–1819.
- 56 J. F. Zimmerman, R. Parameswaran, G. Murray, Y. Wang, M. Burke and B. Tian, Cellular uptake and dynamics of unlabeled freestanding silicon nanowires, *Sci. Adv.*, 2016, **2**(12), e1601039.
- 57 J. McCarthy, I. Inkielewicz-Stepniak, J. J. Corbalan and M. W. Radomski, Mechanisms of toxicity of amorphous silica nanoparticles on human lung submucosal cells *in vitro*: protective effects of fisetin, *Chem. Res. Toxicol.*, 2012, **25**(10), 2227–2235.
- 58 R. Salomoni, P. Léo, A. F. Montemor, B. G. Rinaldi and M. F. A. Rodrigues, Antibacterial effect of silver nanoparticles in *Pseudomonas aeruginosa*, *Nanotechnol. Sci. Appl.*, 2017, 115–121.
- 59 W. Liu, Y. Wu, C. Wang, H. C. Li, T. Wang, C. Y. Liao, L. Cui, Q. F. Zhou, B. Yan and G. B. Jiang, Impact of silver nanoparticles on human cells: effect of particle size, *Nanotoxicology*, 2010, **4**(3), 319–330.
- 60 R. Krishnan, V. Arumugam and S. K. Vasaviah, The MIC and MBC of silver nanoparticles against *Enterococcus faecalis* - a facultative anaerobe, *J. Nanomed. Nanotechnol.*, 2015, **6**(3), 285.
- 61 J. M. Conlon, E. Ahmed and E. Condamine, Antimicrobial properties of brevinin-2-related peptide and its analogs:



- efficacy against multidrug-resistant *Acinetobacter baumannii*, *Chem. Biol. Drug Des.*, 2009, **74**(5), 488–493.
- 62 J. M. Conlon, E. Ahmed, L. Coquet, T. Jouenne, J. Leprince, H. Vaudry and J. D. King, Peptides with potent cytolytic activity from the skin secretions of the North American leopard frogs, *Lithobates blairi* and *Lithobates yavapaiensis*, *Toxicon*, 2009, **53**(7–8), 699–705.
- 63 L.-H. Peng, Y.-F. Huang, C.-Z. Zhang, J. Niu, Y. Chen, Y. Chu, Z.-H. Jiang, J.-Q. Gao and Z.-W. Mao, Integration of antimicrobial peptides with gold nanoparticles as unique non-viral vectors for gene delivery to mesenchymal stem cells with antibacterial activity, *Biomaterials*, 2016, **103**, 137–149.
- 64 C. Zannella, S. Shinde, M. Vitiello, A. Falanga, E. Galdiero, A. Fahmi, B. Santella, L. Nucci, R. Gasparro, M. Galdiero, *et al.*, Antibacterial activity of indolicidin-coated silver nanoparticles in oral disease, *Appl. Sci.*, 2020, **10**(5), 1837.
- 65 L. M. Browning, K. J. Lee, P. D. Nallathamby, P. K. Cherukuri, T. Huang, S. Warren and X. N. Xu, Single Nanoparticle Plasmonic Spectroscopy for Study of Charge-Dependent Efflux Function of Multidrug ABC Transporters of Single Live *Bacillus subtilis* Cells, *J. Phys. Chem. C. Nanomater. Interfaces*, 2016, **120**(37), 21007–21016, DOI: [10.1021/acs.jpcc.6b03313](https://doi.org/10.1021/acs.jpcc.6b03313).
- 66 K. J. Lee, L. M. Browning, P. D. Nallathamby and X. H. Xu, Study of charge-dependent transport and toxicity of peptide-functionalized silver nanoparticles using zebrafish embryos and single nanoparticle plasmonic spectroscopy, *Chem. Res. Toxicol.*, 2013, **26**(6), 904–917, DOI: [10.1021/tx400087d](https://doi.org/10.1021/tx400087d).
- 67 M. Maqueda, A. Gálvez, M. M. Bueno, M. J. Sanchez-Barrena, C. González, A. Albert, M. Rico and E. Valdivia, Peptide AS-48: prototype of a new class of cyclic bacteriocins, *Curr. Protein Pept. Sci.*, 2004, **5**(5), 399–416.
- 68 P. D. Nallathamby, J. Hopf, L. E. Irimata, T. L. McGinnity and R. K. Roeder, Preparation of fluorescent Au-SiO<sub>2</sub> core-shell nanoparticles and nanorods with tunable silica shell thickness and surface modification for immunotargeting, *J. Mater. Chem. B*, 2016, **4**(32), 5418–5428, DOI: [10.1039/c6tb01659f](https://doi.org/10.1039/c6tb01659f).
- 69 W. Wang, P. D. Nallathamby, C. M. Foster, J. L. Morrell-Falvey, N. P. Mortensen, M. J. Doktycz, B. Gu and S. T. Retterer, Volume labeling with Alexa Fluor dyes and surface functionalization of highly sensitive fluorescent silica (SiO<sub>2</sub>) nanoparticles, *Nanoscale*, 2013, **5**(21), 10369–10375, DOI: [10.1039/c3nr02639f](https://doi.org/10.1039/c3nr02639f).
- 70 M. Waters, J. Hopf, E. Tam, S. Wallace, J. Chang, Z. Bennett, H. Aquino, R. K. Roeder, P. Helquist, M. S. Stack, *et al.*, Biocompatible, Multi-Mode, Fluorescent, T<sub>2</sub> MRI Contrast Magnetoelectric-Silica Nanoparticles (MagSiNs), for On-Demand Doxorubicin Delivery to Metastatic Cancer Cells, *Pharmaceuticals*, 2022, **15**(10), 1216.
- 71 Y. Zhang, P. D. Nallathamby, G. D. Vigil, A. A. Khan, D. E. Mason, J. D. Boerckel, R. K. Roeder and S. S. Howard, Super-resolution fluorescence microscopy by stepwise optical saturation, *Biomed. Opt. Express*, 2018, **9**(4), 1613–1629, DOI: [10.1364/BOE.9.001613](https://doi.org/10.1364/BOE.9.001613).
- 72 X.-H. N. Xu, Y. Song and P. Nallathamby, Probing membrane transport of single live cells using single-molecule detection and single nanoparticle assay, in *New Frontiers in Ultrasensitive Bioanalysis*, 2007, pp. 41–70.
- 73 I. M. Frick, M. Morgelin and L. Bjorck, Virulent aggregates of *Streptococcus pyogenes* are generated by homophilic protein-protein interactions, *Mol. Microbiol.*, 2000, **37**(5), 1232–1247, DOI: [10.1046/j.1365-2958.2000.02084.x](https://doi.org/10.1046/j.1365-2958.2000.02084.x).
- 74 J. Kim, M. Yeom, T. Lee, H. O. Kim, W. Na, A. Kang, J. W. Lim, G. Park, C. Park, D. Song, *et al.*, Porous gold nanoparticles for attenuating infectivity of influenza A virus, *J. Nanobiotechnol.*, 2020, **18**(1), 54, DOI: [10.1186/s12951-020-00611-8](https://doi.org/10.1186/s12951-020-00611-8).
- 75 Y. Lyu, L. M. Becerril, M. Vanzan, S. Corni, M. Cattelan, G. Granozzi, M. Frascioni, P. Rajak, P. Banerjee, R. Ciancio, *et al.*, The Interaction of Amines with Gold Nanoparticles, *Adv. Mater.*, 2023, 2211624.
- 76 G. Xie, J. Sun, G. Zhong, L. Shi and D. Zhang, Biodistribution and toxicity of intravenously administered silica nanoparticles in mice, *Arch. Toxicol.*, 2010, **84**, 183–190.
- 77 T. Yu, D. Hubbard, A. Ray and H. Ghandehari, *In vivo* biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics, *J. Controlled Release*, 2012, **163**(1), 46–54.
- 78 R. Kumar, I. Roy, T. Y. Ohulchanskyy, L. A. Vathy, E. J. Bergey, M. Sajjad and P. N. Prasad, *In vivo* biodistribution and clearance studies using multimodal organically modified silica nanoparticles, *ACS Nano*, 2010, **4**(2), 699–708.
- 79 E. A. Steele, C. Breen, E. Campbell and R. Martin, Food regulations and enforcement in the USA, in *Reference Module in Food Science*, Elsevier, 2016.

